category	number_of_genes	p_value	fdr	description
Process	181	4.35e-220	6.83e-216	DNA metabolic process
Process	150	1.01e-184	7.940000000000001e-181	DNA repair
Process	158	2.57e-176	1.34e-172	Cellular response to DNA damage stimulus
Process	189	1.6100000000000002e-160	6.32e-157	Nucleic acid metabolic process
RCTM	122	2.07e-155	4.72e-152	DNA Repair
NetworkNeighborAL	104	2.04e-148	9.31e-145	DNA repair pathways, full network, and HDR through Homologous Recombination (HRR)
Keyword	123	2.1999999999999998e-147	1.48e-144	DNA damage
Process	185	1.9e-142	4.96e-139	Cellular macromolecule metabolic process
Keyword	114	6.3399999999999996e-139	2.13e-136	DNA repair
Process	160	1.6600000000000002e-132	2.88e-129	Cellular response to stress
Process	100	7.09e-132	1.11e-128	DNA replication
NetworkNeighborAL	91	8.53e-131	1.95e-127	DNA repair pathways, full network, and HDR through Homologous Recombination (HRR)
NetworkNeighborAL	88	4.67e-127	7.130000000000001e-124	DNA repair pathways, full network, and HDR through Homologous Recombination (HRR)
COMPARTMENTS	134	4.29e-121	9.88e-118	Chromosome
NetworkNeighborAL	80	1.58e-115	1.8e-112	Mixed, incl. Fanconi anemia pathway, and DNA repair complex
WikiPathways	82	3.09e-115	2.41e-112	DNA repair pathways, full network
RCTM	84	7.06e-113	8.06e-110	DNA Double-Strand Break Repair
NetworkNeighborAL	77	1.04e-111	9.550000000000001e-109	DNA repair pathways, full network, and HDR through Homologous Recombination (HRR)
Process	88	1.6100000000000002e-110	1.95e-107	Double-strand break repair
PMID	84	4.82e-114	2.11e-107	(2012) Exonuclease 1 (EXO1) gene variation and melanoma risk.
Process	81	7.47e-110	8.37e-107	DNA-templated DNA replication
Component	184	6.37e-102	1.3e-98	Nucleoplasm
COMPARTMENTS	190	4e-101	4.6e-98	Nucleus
Component	186	7.91e-99	8.099999999999999e-96	Nuclear lumen
Process	83	9.18e-98	9.599999999999999e-95	DNA recombination
RCTM	72	1.79e-97	1.36e-94	Homology Directed Repair
Process	196	6.999999999999999e-97	6.869999999999999e-94	Macromolecule metabolic process
RCTM	104	1.12e-93	6.4e-91	Cell Cycle
PMID	71	6.17e-97	1.35e-90	(2019) DNA damage response and repair in perspective: Aedes aegypti, Drosophila melanogaster and Homo sapiens.
Component	139	4.55e-92	3.1e-89	Chromosome
COMPARTMENTS	139	4.55e-92	3.49e-89	Nuclear lumen
Function	78	2.1e-91	1.04e-87	Catalytic activity, acting on DNA
NetworkNeighborAL	62	2.5699999999999997e-89	1.9600000000000002e-86	Diseases of DNA repair, and DNA repair complex
RCTM	66	3.6e-88	1.6400000000000002e-85	HDR through Homologous Recombination (HRR) or Single Strand Annealing (SSA)
Process	162	6.45e-86	5.9499999999999996e-83	Response to stress
Process	196	2.41e-85	2.1e-82	Nitrogen compound metabolic process
PMID	63	5.64e-88	8.25e-82	(2014) DNA repair in cancer: emerging targets for personalized therapy.
Process	195	2.1e-84	1.73e-81	Cellular metabolic process
Component	187	4.54e-83	2.32e-80	Intracellular organelle lumen
Keyword	183	1.7199999999999998e-82	3.86e-80	Nucleus
NetworkNeighborAL	56	1.06e-82	6.900000000000001e-80	DNA replication, and Regulation of DNA-directed DNA polymerase activity
PMID	65	1.11e-83	1.22e-77	(2010) The DNA damage response: making it safe to play with knives.
Keyword	59	4.7700000000000003e-79	8.02e-77	DNA replication
PMID	59	1.71e-82	1.5e-76	(2019) DNA Damage Response Pathways in Dinoflagellates.
PMID	60	1.86e-82	1.5e-76	(2021) DNA folds threaten genetic stability and can be leveraged for chemotherapy.
Process	196	3.6e-79	2.82e-76	Primary metabolic process
RCTM	54	1.7400000000000002e-77	6.6e-75	HDR through Homologous Recombination (HRR)
Process	60	5.2800000000000005e-77	3.94e-74	Recombinational repair
PMID	60	8.11e-79	5.08e-73	(2014) Emergence and evolutionary analysis of the human DDR network: implications in comparative genomics and downstream analyses.
PMID	59	1.88e-78	1.03e-72	(2015) DNA repair mechanisms in cancer development and therapy.
PMID	56	3.22e-77	1.57e-71	(2013) DNA damage tolerance: a double-edged sword guarding the genome.
Process	85	2.52e-74	1.72e-71	Regulation of DNA metabolic process
Component	196	2.1500000000000003e-73	6.29e-71	Nucleus
COMPARTMENTS	151	2.4e-73	1.38e-70	Intracellular non-membrane-bounded organelle
PMID	57	5.17e-76	2.27e-70	(2019) Tissue specificity of DNA damage response and tumorigenesis.
Process	57	1.1e-72	7.17e-70	Double-strand break repair via homologous recombination
PMID	57	2.0000000000000002e-75	7.99e-70	(2017) Mechanisms of DNA damage, repair, and mutagenesis.
Function	137	3.75e-73	9.24e-70	DNA binding
PMID	56	6.73e-75	2.4599999999999997e-69	(2021) Mass spectrometry-based protein-protein interaction techniques and their applications in studies of DNA damage repair.
Process	197	6.77e-72	4.2499999999999997e-69	Metabolic process
RCTM	58	6.67e-69	2.1700000000000002e-66	G2/M Checkpoints
Component	106	1.25e-68	3.2e-66	Nuclear protein-containing complex
WikiPathways	51	8.669999999999999e-69	3.3800000000000004e-66	DNA IR-damage and cellular response via ATR
COMPARTMENTS	173	1.3199999999999998e-68	5.07e-66	Protein-containing complex
COMPARTMENTS	140	2.2e-68	7.24e-66	Intracellular organelle lumen
PMID	53	1.7199999999999998e-68	5.8e-63	(2015) Modulation of DNA damage and repair pathways by human tumour viruses.
PMID	58	3.2399999999999997e-68	1.01e-62	(2021) Proteins from the DNA Damage Response: Regulation, Dysfunction, and Anticancer Strategies.
Process	102	2.25e-65	1.36e-62	Cell cycle
Function	80	9.410000000000001e-66	1.55e-62	Catalytic activity, acting on a nucleic acid
RCTM	64	1.74e-64	4.9799999999999995e-62	Cell Cycle Checkpoints
PMID	54	4.41e-67	1.2899999999999999e-61	(2020) Focus on UV-Induced DNA Damage and Repair-Disease Relevance and Protective Strategies.
PMID	50	7.049999999999999e-67	1.93e-61	(2016) The multifaceted influence of histone deacetylases on DNA damage signalling and DNA repair.
RCTM	55	2.95e-63	7.49e-61	DNA Replication
RCTM	55	1.67e-62	3.82e-60	S Phase
NetworkNeighborAL	43	1.23e-62	7.06e-60	Homologous DNA Pairing and Strand Exchange, and Response to intra-S DNA damage checkpoint signaling
Process	87	2.12e-62	1.23e-59	Cell cycle process
COMPARTMENTS	96	1.07e-61	2.46e-59	Nucleoplasm
RCTM	50	2.45e-60	5.08e-58	Synthesis of DNA
COMPARTMENTS	191	2.73e-60	5.71e-58	Intracellular membrane-bounded organelle
PMID	48	2.67e-63	6.88e-58	(2021) miR-27b-3p a Negative Regulator of DSB-DNA Repair.
PMID	45	4.23e-63	1.0300000000000001e-57	(2011) Comprehensive screen of genetic variation in DNA repair pathway genes and postmenopausal breast cancer risk.
COMPARTMENTS	44	8.52e-60	1.63e-57	Replication fork
PMID	44	7.96e-63	1.8400000000000002e-57	(2020) Identification of the DNA Replication Regulator MCM Complex Expression and Prognostic Significance in Hepatic Carcinoma.
PMID	47	8.370000000000001e-63	1.8400000000000002e-57	(2021) DNA Damage Response in Multiple Myeloma: The Role of the Tumor Microenvironment.
PMID	45	1.25e-62	2.61e-57	(2021) Targeting protein-protein interactions in the DNA damage response pathways for cancer chemotherapy.
Process	89	1.0400000000000001e-59	5.810000000000001e-57	Chromosome organization
PMID	45	6.04e-62	1.2e-56	(2013) DNA double-strand break repair as determinant of cellular radiosensitivity to killing and target in radiation therapy.
PMID	44	1.34e-61	2.55e-56	(2020) Inhibition of DNA Repair in Cancer Therapy: Toward a Multi-Target Approach.
PMID	46	6.429999999999999e-61	1.1699999999999999e-55	(2021) Targeting the Interplay between HDACs and DNA Damage Repair for Myeloma Therapy.
PMID	46	1.01e-60	1.77e-55	(2020) Chromosome Instability in Fanconi Anemia: From Breaks to Phenotypic Consequences.
PMID	44	1.1199999999999999e-60	1.9e-55	(2019) Treatment May Be Harmful: MechanismsPredictionPrevention of Drug-Induced DNA Damage and Repair in Multiple Myeloma.
PMID	45	1.19e-60	1.94e-55	(2019) beta-HPV 8E6 Attenuates ATM and ATR Signaling in Response to UV Damage.
PMID	46	2.45e-60	3.84e-55	(2018) Ubiquitylation at the Fork: Making and Breaking Chains to Complete DNA Replication.
PMID	46	2.45e-60	3.84e-55	(2017) Around and beyond 53BP1 Nuclear Bodies.
RCTM	39	3.46e-57	6.589999999999999e-55	Homologous DNA Pairing and Strand Exchange
PMID	45	4.93e-60	7.21e-55	(2009) Family cancer syndromes: inherited deficiencies in systems for the maintenance of genomic integrity.
PMID	43	7.219999999999999e-60	1.0199999999999998e-54	(2012) DNA replication stress response involving PLK1, CDC6, POLQ, RAD51 and CLASPIN upregulation prognoses the outcome of earlymid-stage non-small cell lung cancer patients.
RCTM	40	7.81e-57	1.37e-54	Diseases of DNA repair
COMPARTMENTS	40	4.23e-56	7.48e-54	DNA repair complex
Component	41	3.3e-56	7.499999999999999e-54	Replication fork
PMID	52	6.88e-59	9.429999999999999e-54	(2014) A fine-scale dissection of the DNA double-strand break repair machinery and its implications for breast cancer therapy.
PMID	42	7.62e-59	1.01e-53	(2019) The Fanconi Anemia Pathway in Cancer.
Component	56	1.4999999999999999e-55	3.06e-53	Nuclear chromosome
PMID	43	2.61e-58	3.37e-53	(2020) DNA repair fidelity in stem cell maintenance, health, and disease.
WikiPathways	38	2.04e-55	5.31e-53	DNA replication
COMPARTMENTS	60	4.27e-55	7.02e-53	Nuclear chromosome
Component	163	4.11e-55	7.65e-53	Protein-containing complex
KEGG	39	7.479999999999999e-55	2.5099999999999998e-52	Fanconi anemia pathway
RCTM	37	1.75e-54	2.8599999999999996e-52	Presynaptic phase of homologous DNA pairing and strand exchange
RCTM	37	3.35e-54	5.1e-52	Defective homologous recombination repair (HRR) due to BRCA2 loss of function
PMID	41	1.17e-56	1.47e-51	(2018) Deoxyribonucleic Acid Damage and Repair: Capitalizing on Our Understanding of the Mechanisms of Maintaining Genomic Integrity for Therapeutic Purposes.
PMID	42	1.2900000000000001e-56	1.57e-51	(2021) Analyzing the Opportunities to Target DNA Double-Strand Breaks Repair and Replicative Stress Responses to Improve Therapeutic Index of Colorectal Cancer.
Component	158	1.14e-53	1.95e-51	Intracellular non-membrane-bounded organelle
Process	171	3.6299999999999996e-54	1.96e-51	Cellular response to stimulus
RCTM	48	1.51e-53	2.03e-51	Mitotic G1 phase and G1/S transition
PMID	44	1.8e-56	2.13e-51	(2016) Balancing self-renewal against genome preservation in stem cells: How do they manage to have the cake and eat it too?
PMID	41	1.9800000000000001e-56	2.28e-51	(2020) DNA Repair Syndromes and Cancer: Insights Into Genetics and Phenotype Patterns.
PMID	42	3.3500000000000003e-56	3.77e-51	(2021) DNA Damage Repair Deficiency in Pancreatic Ductal Adenocarcinoma: Preclinical Models and Clinical Perspectives.
PMID	41	5.4700000000000005e-56	6e-51	(2021) Genomic Instability and Cancer Risk Associated with Erroneous DNA Repair.
PMID	41	5.4700000000000005e-56	6e-51	(2020) DNA Damage: From Threat to Treatment.
PMID	40	7.2999999999999995e-56	7.62e-51	(2020) The FANCBRCA Pathway Releases Replication Blockades by Eliminating DNA Interstrand Cross-Links.
Function	143	7.399999999999999e-54	9.13e-51	Nucleic acid binding
RCTM	46	9.93e-53	1.26e-50	G1/S Transition
PMID	41	1.4799999999999999e-55	1.51e-50	(2015) Hsp90: A New Player in DNA Repair?
Process	64	2.97e-53	1.55e-50	Regulation of cell cycle phase transition
PMID	44	1.9799999999999998e-55	1.97e-50	(2018) Integrating the DNA damage and protein stress responses during cancer development and treatment.
PMID	45	2.07e-55	2.01e-50	(2019) Functional Analysis of the Replication Fork Proteome Identifies BET Proteins as PCNA Regulators.
PMID	40	6.0199999999999994e-55	5.74e-50	(2019) Holding All the Cards-How Fanconi Anemia Proteins Deal with Replication Stress and Preserve Genomic Stability.
PMID	38	7.05e-55	6.58e-50	(2014) Molecular mechanisms of DNA replication checkpoint activation.
RCTM	67	5.8399999999999994e-52	7.02e-50	Cell Cycle, Mitotic
PMID	42	7.919999999999999e-55	7.24e-50	(2019) Proteolytic control of genome integrity at the replication fork.
PMID	40	9.999999999999999e-55	8.97e-50	(2020) Evolving insights: how DNA repair pathways impact cancer evolution.
PMID	38	1.2899999999999998e-54	1.13e-49	(2012) Rescue of replication failure by Fanconi anaemia proteins.
PMID	37	1.75e-54	1.51e-49	(2018) Rare Genetic Diseases with Defects in DNA Repair: Opportunities and Challenges in Orphan Drug Development for Targeted Cancer Therapy.
PMID	42	1.87e-54	1.58e-49	(2021) A Link between Replicative Stress, Lamin Proteins, and Inflammation.
RCTM	35	1.66e-51	1.89e-49	Activation of ATR in response to replication stress
PMID	40	7.209999999999999e-54	5.96e-49	(2017) Maintenance of genome stability by Fanconi anemia proteins.
PMID	38	7.449999999999999e-54	6.05e-49	(2016) Interplay between Fanconi anemia and homologous recombination pathways in genome integrity.
RCTM	40	1.18e-50	1.2799999999999999e-48	Processing of DNA double-strand break ends
PMID	46	1.64e-53	1.3099999999999999e-48	(2018) DNA Checkpoint and Repair Factors Are Nuclear Sensors for Intracellular Organelle Stresses-Inflammations and Cancers Can Have High Genomic Risks.
PMID	39	1.82e-53	1.43e-48	(2016) Cellular response to DNA interstrand crosslinks: the Fanconi anemia pathway.
PMID	43	2.53e-53	1.94e-48	(2018) Mechanisms of Oncogene-Induced Replication Stress: Jigsaw Falling into Place.
Process	47	4.96e-51	2.51e-48	Cell cycle checkpoint signaling
PMID	38	6.81e-53	5.1499999999999993e-48	(2021) Mind the replication gap.
Function	39	5.24e-51	5.17e-48	Damaged DNA binding
COMPARTMENTS	193	3.71e-50	5.33e-48	Intracellular organelle
PMID	36	1.0299999999999999e-52	7.67e-48	(2014) DNA double-strand break repair pathway choice and cancer.
Process	45	1.8e-50	8.839999999999999e-48	Regulation of DNA replication
RCTM	34	9.64e-50	1e-47	HDR through Single Strand Annealing (SSA)
Process	43	2.29e-50	1.09e-47	DNA integrity checkpoint signaling
PMID	39	2.1399999999999997e-52	1.57e-47	(2017) The essential kinase ATR: ensuring faithful duplication of a challenging genome.
RCTM	33	4.08e-49	4.05e-47	Activation of the pre-replicative complex
PMID	37	6.97e-52	5.010000000000001e-47	(2020) Under-Replicated DNA: The Byproduct of Large Genomes?
PMID	38	9.059999999999999e-52	6.4e-47	(2017) The Role of PALB2 in the DNA Damage Response and Cancer Predisposition.
PMID	37	2.06e-51	1.4299999999999999e-46	(2018) Methodologies for Improving HDR Efficiency.
Process	40	3.54e-49	1.63e-46	DNA duplex unwinding
PMID	38	3.93e-51	2.69e-46	(2017) Drugging the Cancers Addicted to DNA Repair.
PMID	39	5.24e-51	3.54e-46	(2013) Human single-stranded DNA binding proteins are essential for maintaining genomic stability.
PMID	36	6.93e-51	4.6e-46	(2021) Shaping the BRCAness mutational landscape by alternative double-strand break repair, replication stress and mitotic aberrancies.
PMID	37	9.85e-51	6.44e-46	(2013) DNA methyltransferases, DNA damage repair, and cancer.
PMID	35	1.11e-50	7.14e-46	(2015) Ionizing radiation-induced DNA injury and damage detection in patients with breast cancer.
Process	41	1.61e-48	7.21e-46	DNA conformation change
PMID	36	1.21e-50	7.71e-46	(2010) DNA interstrand crosslink repair in mammalian cells: step by step.
PMID	39	1.9e-50	1.1899999999999999e-45	(2020) Protective Mechanisms Against DNA Replication Stress in the Nervous System.
PMID	37	2.69e-50	1.6599999999999998e-45	(2019) PARP inhibitors in ovarian cancer: Sensitivity prediction and resistance mechanisms.
PMID	36	3.62e-50	2.21e-45	(2011) Genetic variation in DNA repair pathway genes and melanoma risk.
Process	40	5.75e-48	2.4399999999999998e-45	Telomere maintenance
PMID	36	6.18e-50	3.71e-45	(2014) Human RecQ helicases in DNA repair, recombination, and replication.
PMID	35	6.66e-50	3.9499999999999996e-45	(2015) Exploiting the Fanconi Anemia Pathway for Targeted Anti-Cancer Therapy.
RCTM	32	4.64e-47	4.41e-45	Impaired BRCA2 binding to RAD51
PMID	34	9.64e-50	5.639999999999999e-45	(2017) Recent discoveries in the molecular pathogenesis of the inherited bone marrow failure syndrome Fanconi anemia.
PMID	36	1.05e-49	6.039999999999999e-45	(2013) Genomic instability in cancer.
PMID	38	1.4999999999999998e-49	8.56e-45	(2020) Impact of Helicobacter pylori Infection and Its Major Virulence Factor CagA on DNA Damage Repair.
PMID	36	1.76e-49	9.88e-45	(2020) A Survey of Essential Genome Stability Genes Reveals That Replication Stress Mitigation Is Critical for Peri-Implantation Embryogenesis.
WikiPathways	36	5.1e-47	9.949999999999999e-45	G1 to S cell cycle control
PMID	37	1.85e-49	1.03e-44	(2018) Germline Pathogenic Variants in Homologous Recombination and DNA Repair Genes in an Asian Cohort of Young-Onset Colorectal Cancer.
PMID	37	1.85e-49	1.03e-44	(2013) DNA repair mechanisms in dividing and non-dividing cells.
Process	67	2.89e-47	1.19e-44	Mitotic cell cycle
Component	43	1.08e-46	1.57e-44	Chromosome, telomeric region
PMID	38	3.54e-49	1.92e-44	(2020) DNA Repair and Ovarian Carcinogenesis: Impact on Risk, Prognosis and Therapy Outcome.
RCTM	37	2.45e-46	2.24e-44	G2/M DNA damage checkpoint
Component	33	1.87e-46	2.55e-44	DNA repair complex
PMID	34	6.17e-49	3.3e-44	(2017) Non-homologous DNA end joining and alternative pathways to double-strand break repair.
PMID	35	6.32e-49	3.34e-44	(2017) DNA damage response and cancer therapeutics through the lens of the Fanconi Anemia DNA repair pathway.
PMID	35	6.32e-49	3.34e-44	(2013) Advances in understanding the complex mechanisms of DNA interstrand cross-link repair.
WikiPathways	38	2.5e-46	3.9e-44	Retinoblastoma gene in cancer
Process	63	1.15e-46	4.64e-44	Mitotic cell cycle process
PMID	35	1.08e-48	5.59e-44	(2009) The Fanconi anemia protein interaction network: casting a wide net.
PMID	35	1.84e-48	9.4e-44	(2013) DNA helicases involved in DNA repair and their roles in cancer.
PMID	34	2.01e-48	1.01e-43	(2011) DNA interstrand crosslink repair and cancer.
PMID	36	3.37e-48	1.6800000000000002e-43	(2021) RAD52: Paradigm of Synthetic Lethality and New Developments.
Process	48	4.5e-46	1.7700000000000002e-43	Negative regulation of cell cycle phase transition
PMID	33	5.479999999999999e-48	2.7e-43	(2018) DNA repair pathways and cisplatin resistance: an intimate relationship.
PMID	37	6.549999999999999e-48	3.19e-43	(2015) Repeat instability during DNA repair: Insights from model systems.
PMID	37	1.51e-47	7.290000000000001e-43	(2021) Mechanisms of damage tolerance and repair during DNA replication.
PMID	34	3.2200000000000003e-47	1.54e-42	(2017) S-phase checkpoint regulations that preserve replication and chromosome integrity upon dNTP depletion.
Process	68	4.11e-45	1.57e-42	Regulation of cell cycle process
PMID	35	3.7700000000000003e-47	1.7799999999999997e-42	(2020) Fanconi anemia pathway as a prospective target for cancer intervention.
NetworkNeighborAL	31	4.94e-45	2.51e-42	Resolution of D-loop Structures through Holliday Junction Intermediates, and RIDDLE syndrome
PMID	35	6.08e-47	2.8399999999999998e-42	(2017) Targeting DNA Repair in Cancer: Beyond PARP Inhibitors.
RCTM	30	4.16e-44	3.65e-42	DNA strand elongation
COMPARTMENTS	45	3.27e-44	4.18e-42	protein-DNA complex
PMID	37	1.13e-46	5.22e-42	(2021) RIF1 Links Replication Timing with Fork Reactivation and DNA Double-Strand Break Repair.
Function	40	6.48e-45	5.32e-42	Single-stranded DNA binding
PMID	34	1.53e-46	6.979999999999999e-42	(2021) The Safe Path at the Fork: Ensuring Replication-Associated DNA Double-Strand Breaks are Repaired by Homologous Recombination.
PMID	37	1.67e-46	7.53e-42	(2017) Directing the use of DDR kinase inhibitors in cancer treatment.
PMID	37	1.67e-46	7.53e-42	(2022) Targeting DNA Damage Response and Immune Checkpoint for Anticancer Therapy.
PMID	38	1.7499999999999999e-46	7.76e-42	(2014) DNA damage response genes and the development of cancer metastasis.
PMID	34	2.5299999999999998e-46	1.1099999999999999e-41	(2022) Fanconi Anemia Pathway in Colorectal Cancer: A Novel Opportunity for Diagnosis, Prognosis and Therapy.
Process	49	6.47e-44	2.42e-41	Negative regulation of cell cycle process
WikiPathways	39	1.99e-43	2.59e-41	Cell cycle
Process	40	3.41e-43	1.22e-40	Signal transduction in response to DNA damage
RCTM	36	1.71e-42	1.45e-40	Regulation of TP53 Activity through Phosphorylation
NetworkNeighborAL	29	3.2999999999999998e-43	1.51e-40	Activation of the pre-replicative complex, and GINS complex
Function	156	2.61e-43	1.84e-40	Heterocyclic compound binding
Function	38	3.740000000000001e-43	2.31e-40	ATP-dependent activity, acting on DNA
Process	77	1.76e-42	6.13e-40	Regulation of cell cycle
Function	156	1.3399999999999998e-42	7.34e-40	Organic cyclic compound binding
Process	52	2.3699999999999998e-42	8.059999999999999e-40	Negative regulation of cell cycle
Process	37	2.7799999999999996e-42	9.27e-40	DNA damage checkpoint signaling
Process	32	8.479999999999999e-42	2.77e-39	Regulation of DNA-templated DNA replication
RCTM	51	5.03e-41	4.1e-39	Transcriptional Regulation by TP53
Process	55	1.36e-41	4.36e-39	Response to radiation
KEGG	29	2.6e-41	4.36e-39	DNA replication
Process	172	3.08e-41	9.66e-39	Response to stimulus
RCTM	28	1.2799999999999998e-40	1.0099999999999999e-38	Resolution of D-loop Structures through Holliday Junction Intermediates
KEGG	37	1.7299999999999999e-40	1.94e-38	Cell cycle
WikiPathways	33	2.4599999999999998e-40	2.75e-38	Nucleotide excision repair in xeroderma pigmentosum 
Keyword	94	4.939999999999999e-40	6.64e-38	DNA-binding
KEGG	28	4.01e-39	3.3700000000000004e-37	Homologous recombination
COMPARTMENTS	195	1.98e-38	2.4e-36	Intracellular
WikiPathways	31	7.86e-38	7.68e-36	miRNA regulation of DNA damage response
Process	46	4.1000000000000003e-38	1.2600000000000001e-35	Positive regulation of DNA metabolic process
RCTM	27	1.95e-37	1.44e-35	Resolution of Abasic Sites (AP sites)
KEGG	28	2.1700000000000002e-37	1.46e-35	Nucleotide excision repair
Process	33	6.07e-38	1.83e-35	DNA biosynthetic process
Component	48	3.1200000000000003e-37	3.9900000000000003e-35	Chromosomal region
Process	37	1.5700000000000002e-37	4.66e-35	Negative regulation of DNA metabolic process
Keyword	31	6.04e-37	6.760000000000001e-35	DNA recombination
Component	197	6.030000000000001e-37	7.27e-35	Intracellular membrane-bounded organelle
RCTM	37	1.24e-36	8.87e-35	Regulation of TP53 Activity
Process	53	3.79e-37	1.1e-34	Regulation of mitotic cell cycle
WikiPathways	30	1.39e-36	1.21e-34	DNA damage response
RCTM	28	1.9900000000000002e-36	1.38e-34	Extension of Telomeres
WikiPathways	27	3.76e-36	2.94e-34	Nucleotide excision repair
RCTM	26	5.54e-36	3.72e-34	Fanconi Anemia Pathway
Keyword	57	1.29e-35	1.2300000000000001e-33	Cell cycle
RCTM	34	2.36e-35	1.54e-33	DNA Replication Pre-Initiation
Process	28	6.94e-36	1.98e-33	DNA-templated DNA replication maintenance of fidelity
Process	34	1.88e-35	5.2700000000000004e-33	Mitotic cell cycle checkpoint signaling
Process	35	2.55e-35	7.01e-33	Response to ionizing radiation
RCTM	30	1.29e-34	8.16e-33	Global Genome Nucleotide Excision Repair (GG-NER)
RCTM	29	1.33e-34	8.23e-33	Base Excision Repair
HPO	28	8.38e-37	1.02e-32	Abnormality of chromosome stability
Process	26	4.05e-35	1.1e-32	Interstrand cross-link repair
WikiPathways	27	4.0099999999999995e-34	2.85e-32	DNA IR-double strand breaks and cellular response via ATM
NetworkNeighborAL	24	9.13e-35	3.8e-32	Polymerase switching, and Epsilon DNA polymerase complex
Process	24	1.65e-34	4.4e-32	DNA replication initiation
Process	30	2.3199999999999997e-34	6.07e-32	Mitotic DNA integrity checkpoint signaling
RCTM	23	1.43e-33	8.57e-32	Resolution of D-loop Structures through Synthesis-Dependent Strand Annealing (SDSA)
COMPARTMENTS	24	9.01e-34	1.0400000000000001e-31	Nuclear replication fork
RCTM	24	2.61e-33	1.53e-31	Telomere C-strand (Lagging Strand) Synthesis
Process	27	8.62e-34	2.2200000000000002e-31	Nucleotide-excision repair
RCTM	31	4.73e-33	2.6999999999999997e-31	Nucleotide Excision Repair
HPO	50	8.120000000000001e-35	4.96e-31	Intrauterine growth retardation
Process	25	4.42e-33	1.12e-30	Double-strand break repair via nonhomologous end joining
Process	43	4.84e-33	1.2099999999999999e-30	Regulation of mitotic cell cycle phase transition
RCTM	22	2.1900000000000001e-32	1.22e-30	Defective HDR through Homologous Recombination Repair (HRR) due to PALB2 loss of BRCA2/RAD51/RAD51C binding function
RCTM	22	2.1900000000000001e-32	1.22e-30	Defective homologous recombination repair (HRR) due to BRCA1 loss of function
RCTM	22	2.1900000000000001e-32	1.22e-30	Defective HDR through Homologous Recombination Repair (HRR) due to PALB2 loss of BRCA1 binding function
RCTM	22	2.1900000000000001e-32	1.22e-30	Impaired BRCA2 binding to PALB2
RCTM	31	5.97e-32	2.96e-30	Chromosome Maintenance
RCTM	29	6.2e-32	3.01e-30	Telomere Maintenance
RCTM	24	7.61e-32	3.6199999999999995e-30	Dual Incision in GG-NER
Process	28	6.68e-32	1.64e-29	Mitotic DNA damage checkpoint signaling
Process	24	1.8300000000000002e-31	4.4200000000000004e-29	Base-excision repair
RCTM	21	2.12e-30	9.87e-29	Resolution of AP sites via the multiple-nucleotide patch replacement pathway
NetworkNeighborAL	21	3.29e-31	1.26e-28	Resolution of D-loop Structures through Holliday Junction Intermediates, and DNA translocase activity
DISEASES	22	4.08e-32	1.87e-28	Fanconi anemia
Process	34	8.48e-31	2.0099999999999999e-28	Cellular response to radiation
COMPARTMENTS	40	4.3699999999999995e-30	4.79e-28	Transferase complex, transferring phosphorus-containing groups
Keyword	20	9.379999999999999e-30	7.8799999999999995e-28	Fanconi anemia
HPO	35	2.6300000000000004e-31	1.07e-27	Hypermelanotic macule
Process	29	4.7699999999999996e-30	1.1200000000000001e-27	Regulation of cell cycle G2/M phase transition
RCTM	26	2.4700000000000002e-29	1.1300000000000002e-27	Transcription-Coupled Nucleotide Excision Repair (TC-NER)
Process	35	5.28e-30	1.2200000000000002e-27	Negative regulation of mitotic cell cycle
HPO	21	6.2500000000000005e-31	1.27e-27	Pyridoxine-responsive sideroblastic anemia
HPO	22	4.15e-31	1.27e-27	Duodenal stenosis
COMPARTMENTS	21	1.9800000000000002e-29	2.0800000000000004e-27	Replisome
WikiPathways	21	5.56e-29	3.6200000000000004e-27	Base excision repair
HPO	21	2.12e-30	3.69e-27	Aplasia/Hypoplasia of the uvula
HPO	36	2.59e-30	3.69e-27	Irregular hyperpigmentation
HPO	21	2.12e-30	3.69e-27	Absent testis
HPO	39	3.71e-30	4.11e-27	Hyperpigmentation of the skin
Function	25	8.500000000000001e-30	4.19e-27	DNA helicase activity
Process	20	5.98e-29	1.3600000000000002e-26	Nuclear DNA replication
RCTM	19	5.03e-28	2.2500000000000002e-26	PCNA-Dependent Long Patch Base Excision Repair
HPO	38	2.96e-29	3.01e-26	Clinodactyly of the 5th finger
Process	105	1.36e-28	3.01e-26	Organelle organization
HPO	38	3.32e-29	3.1100000000000004e-26	Deviation of the 5th finger
HPO	21	3.35e-29	3.1100000000000004e-26	Abnormal preputium morphology
HPO	21	3.35e-29	3.1100000000000004e-26	Clubbing of toes
Component	27	3.73e-28	3.82e-26	Site of DNA damage
Process	27	1.88e-28	4.09e-26	Regulation of G2/M transition of mitotic cell cycle
Component	34	4.46e-28	4.3500000000000003e-26	protein-DNA complex
RCTM	22	1.9400000000000003e-27	8.5e-26	DNA Damage Bypass
Component	20	9.200000000000001e-28	8.56e-26	Nuclear replication fork
COMPARTMENTS	19	9.279999999999999e-28	9.29e-26	DNA polymerase complex
Process	35	6.1799999999999995e-28	1.33e-25	Meiotic cell cycle
HPO	31	1.82e-28	1.37e-25	Abnormal uvula morphology
HPO	43	1.8000000000000002e-28	1.37e-25	Abnormality of skin pigmentation
HPO	27	3.73e-28	2.39e-25	Hypopigmented skin patches
HPO	21	3.77e-28	2.39e-25	Almond-shaped palpebral fissure
KEGG	20	6.36e-27	3.56e-25	Base excision repair
HPO	22	9.200000000000001e-28	5.099999999999999e-25	Obsolete Abnormality of the ulna
HPO	34	9.73e-28	5.16e-25	Hematological neoplasm
RCTM	18	1.42e-26	6.099999999999999e-25	Lagging Strand Synthesis
RCTM	23	1.52e-26	6.43e-25	Dual incision in TC-NER
Component	18	7.520000000000001e-27	6.69e-25	DNA polymerase complex
HPO	25	1.5400000000000002e-27	7.52e-25	Aplasia/Hypoplasia of the radius
RCTM	62	1.8600000000000002e-26	7.699999999999999e-25	Generic Transcription Pathway
HPO	52	1.79e-27	8.4e-25	Neoplasm
RCTM	72	2.67e-26	1.09e-24	Disease
HPO	33	2.43e-27	1.09e-24	Weight loss
HPO	51	2.4100000000000003e-27	1.09e-24	Neoplasm by anatomical site
HPO	32	2.54e-27	1.09e-24	Abnormal soft palate morphology
Process	37	5.2900000000000005e-27	1.12e-24	Regulation of response to DNA damage stimulus
HPO	24	2.9e-27	1.18e-24	Forearm undergrowth
HPO	43	2.9400000000000004e-27	1.18e-24	Abnormal cellular physiology
HPO	23	3.3500000000000006e-27	1.2799999999999999e-24	Multiple cafe-au-lait spots
HPO	26	3.66e-27	1.3499999999999999e-24	Myelodysplasia
Process	60	7.420000000000001e-27	1.5499999999999998e-24	Response to abiotic stimulus
HPO	29	4.4600000000000006e-27	1.5999999999999999e-24	Aplasia/Hypoplasia of the testes
Process	23	8.410000000000001e-27	1.74e-24	Homologous recombination
HPO	38	6.2600000000000005e-27	2.18e-24	Hypogonadism
Process	18	1.42e-26	2.88e-24	DNA strand elongation
Process	34	2.04e-26	4.11e-24	Nucleic acid phosphodiester bond hydrolysis
Process	21	2.29e-26	4.54e-24	Replication fork processing
HPO	22	1.5600000000000002e-26	5e-24	Hypoplasia of the ulna
HPO	39	2.3800000000000001e-26	7.44e-24	Deviation of finger
NetworkNeighborAL	19	2.51e-26	8.84e-24	DNA repair complex
RCTM	18	2.46e-25	9.83e-24	Gap-filling DNA repair synthesis and ligation in GG-NER
COMPARTMENTS	17	1.0999999999999999e-25	1.0499999999999999e-23	DNA replication preinitiation complex
DISEASES	23	4.5700000000000005e-27	1.0499999999999999e-23	Congenital hypoplastic anemia
RCTM	22	3.3399999999999997e-25	1.3099999999999999e-23	Gap-filling DNA repair synthesis and ligation in TC-NER
Component	23	2.3599999999999997e-25	2.0099999999999997e-23	Site of double-strand break
Function	44	5.39e-26	2.4199999999999998e-23	ATP-dependent activity
HPO	55	8.53e-26	2.4799999999999997e-23	Abnormality of the male genitalia
HPO	21	9.56e-26	2.71e-23	Bicornuate uterus
Process	28	1.64e-25	3.21e-23	Response to UV
HPO	40	3.0099999999999997e-25	7.989999999999999e-23	Clinodactyly
HPO	29	3.72e-25	9.67e-23	Hypopigmentation of the skin
HPO	27	4.16e-25	1.06e-22	Cafe-au-lait spot
RCTM	18	2.8199999999999997e-24	1.07e-22	Recognition of DNA damage by PCNA-containing replication complex
RCTM	19	3.0999999999999997e-24	1.16e-22	Translesion synthesis by Y family DNA polymerases bypasses lesions on DNA template
HPO	21	5e-25	1.24e-22	Arteriovenous malformation
HPO	39	5.84e-25	1.43e-22	Abnormality of the female genitalia
Component	34	1.84e-24	1.45e-22	Transferase complex, transferring phosphorus-containing groups
COMPARTMENTS	52	1.75e-24	1.61e-22	Transferase complex
HPO	57	6.94e-25	1.66e-22	Microcephaly
HPO	24	8.45e-25	1.95e-22	Spina bifida
HPO	28	9.18e-25	2.07e-22	Sloping forehead
HPO	21	9.33e-25	2.07e-22	Meckel diverticulum
HPO	57	9.84e-25	2.14e-22	Decreased head circumference
WikiPathways	17	3.96e-24	2.38e-22	DNA mismatch repair
WikiPathways	19	4.53e-24	2.5300000000000003e-22	ATM signaling pathway
HPO	21	1.2699999999999999e-24	2.71e-22	Abnormal carotid artery morphology
HPO	24	1.2999999999999998e-24	2.74e-22	Aplasia/Hypoplasia of the iris
HPO	22	1.32e-24	2.74e-22	Hydroureter
RCTM	23	1.0199999999999999e-23	3.75e-22	Switching of origins to a post-replicative state
Process	17	2.2999999999999997e-24	4.44e-22	DNA unwinding involved in DNA replication
HPO	58	2.32e-24	4.56e-22	Short stature
HPO	34	2.73e-24	5.29e-22	Joint dislocation
COMPARTMENTS	69	6.11e-24	5.4e-22	Catalytic complex
HPO	57	3.4099999999999995e-24	6.41e-22	Abnormal reproductive system morphology
HPO	60	3.55e-24	6.56e-22	Abnormality of body height
HPO	49	4.53e-24	8.25e-22	Abnormal testis morphology
Process	20	4.39e-24	8.4e-22	Mitotic G2/M transition checkpoint
COMPARTMENTS	16	1.1099999999999999e-23	9.45e-22	Nuclear replisome
Process	22	6.17e-24	1.1700000000000001e-21	Cellular response to ionizing radiation
HPO	31	6.75e-24	1.21e-21	Microphthalmia
HPO	44	7.61e-24	1.3300000000000001e-21	Cryptorchidism
HPO	33	9.159999999999999e-24	1.57e-21	Hypospadias
HPO	21	9.47e-24	1.6e-21	Triphalangeal thumb
HPO	32	1.2099999999999999e-23	2.0200000000000003e-21	Abnormality of globe size
HPO	21	1.2399999999999999e-23	2.0500000000000003e-21	Tracheoesophageal fistula
HPO	52	1.2399999999999999e-23	2.0500000000000003e-21	Abnormality of male external genitalia
HPO	24	1.47e-23	2.36e-21	Abnormality of the choanae
RCTM	63	6.579999999999999e-23	2.38e-21	Gene expression (Transcription)
HPO	60	2.1699999999999998e-23	3.39e-21	Aplasia/Hypoplasia of the cerebrum
TISSUES	35	1.43e-24	3.47e-21	Cervical carcinoma cell
HPO	41	2.4899999999999998e-23	3.850000000000001e-21	Puberty and gonadal disorders
HPO	61	3.2000000000000003e-23	4.8800000000000004e-21	Abnormality of the genital system
HPO	24	3.75e-23	5.5100000000000004e-21	Anal atresia
Function	20	1.54e-23	6.34e-21	Deoxyribonuclease activity
RCTM	19	1.87e-22	6.680000000000001e-21	Nonhomologous End-Joining (NHEJ)
Process	27	3.6699999999999995e-23	6.7e-21	Negative regulation of mitotic cell cycle phase transition
HPO	59	4.78e-23	6.95e-21	Decreased body weight
COMPARTMENTS	15	8.61e-23	7.080000000000001e-21	Fanconi anaemia nuclear complex
COMPARTMENTS	15	8.61e-23	7.080000000000001e-21	Mre11 complex
HPO	23	5.34e-23	7.670000000000001e-21	Recurrent urinary tract infections
RCTM	17	2.68e-22	9.410000000000001e-21	Termination of translesion DNA synthesis
HPO	44	7.929999999999999e-23	1.11e-20	Micrognathia
HPO	23	7.929999999999999e-23	1.11e-20	Choanal atresia
HPO	44	8.4e-23	1.15e-20	Aplasia/Hypoplasia of the mandible
COMPARTMENTS	15	1.65e-22	1.27e-20	Nonhomologous end joining complex
HPO	24	1.1e-22	1.48e-20	Abnormal uterus morphology
Process	15	8.61e-23	1.55e-20	DNA strand elongation involved in DNA replication
Function	26	4.38e-23	1.66e-20	Helicase activity
HPO	34	1.27e-22	1.71e-20	Abnormality of the urethra
COMPARTMENTS	15	3.09e-22	2.29e-20	Nucleotide-excision repair complex
HPO	44	1.94e-22	2.55e-20	Abnormal long bone morphology
RCTM	16	7.810000000000001e-22	2.7e-20	Polymerase switching on the C-strand of the telomere
HPO	25	3.01e-22	3.9e-20	Clubbing
RCTM	20	1.16e-21	3.96e-20	Orc1 removal from chromatin
HPO	22	3.44e-22	4.42e-20	Azoospermia
HPO	46	3.55e-22	4.51e-20	Abnormal calvaria morphology
HPO	59	4.19e-22	5.27e-20	Abnormality of skull size
HPO	24	4.23e-22	5.27e-20	Short palpebral fissure
Function	16	1.82e-22	6.4e-20	DNA-directed DNA polymerase activity
DISEASES	69	6.53e-23	7.25e-20	Autosomal recessive disease
DISEASES	16	6.31e-23	7.25e-20	Xeroderma pigmentosum
HPO	43	6.1000000000000005e-22	7.51e-20	Abnormality of reproductive system physiology
HPO	23	6.15e-22	7.51e-20	Abnormal spermatogenesis
Function	28	2.34e-22	7.7e-20	Nuclease activity
Component	198	1.4400000000000001e-21	1.09e-19	Intracellular anatomical structure
Process	198	6.23e-22	1.09e-19	Cellular process
HPO	24	9.46e-22	1.14e-19	Abnormal tracheal morphology
HPO	23	1.04e-21	1.24e-19	Abnormal morphology of ulna
HPO	23	1.24e-21	1.46e-19	Facial asymmetry
Process	28	8.56e-22	1.48e-19	Regulation of DNA repair
RCTM	14	4.6e-21	1.55e-19	Processive synthesis on the lagging strand
Keyword	149	2.1800000000000003e-21	1.63e-19	Phosphoprotein
HPO	26	1.4700000000000001e-21	1.73e-19	Abnormal morphology of the radius
COMPARTMENTS	194	2.6300000000000002e-21	1.89e-19	Cellular anatomical entity
COMPARTMENTS	37	2.7200000000000002e-21	1.9e-19	Chromatin
HPO	21	1.78e-21	2.07e-19	External ear malformation
HPO	62	1.82e-21	2.1e-19	Growth delay
Component	47	3.14e-21	2.3e-19	Transferase complex
COMPARTMENTS	21	4.040000000000001e-21	2.73e-19	Site of DNA damage
HPO	62	2.4400000000000002e-21	2.78e-19	Aplasia/Hypoplasia involving the central nervous system
HPO	42	2.51e-21	2.84e-19	Abnormal lower limb bone morphology
Component	14	4.6e-21	3.25e-19	Replisome
HPO	30	3.2100000000000004e-21	3.59e-19	Anorectal anomaly
KEGG	15	8.010000000000001e-21	3.84e-19	Mismatch repair
HPO	21	4.040000000000001e-21	4.48e-19	Leukopenia
HPO	16	4.4900000000000005e-21	4.94e-19	Chromosome breakage
Component	45	7.28e-21	4.97e-19	Intracellular protein-containing complex
NetworkNeighborAL	15	1.73e-21	5.64e-19	Fanconi anaemia nuclear complex, and Fanconi anemia complementation group I
KEGG	24	1.37e-20	5.73e-19	Cellular senescence
HPO	24	5.8200000000000005e-21	6.34e-19	Abnormal localization of kidney
HPO	61	6.430000000000001e-21	6.94e-19	Abnormality of body weight
NetworkNeighborAL	14	2.4e-21	7.33e-19	Fanconi anaemia nuclear complex
NetworkNeighborAL	14	2.4e-21	7.33e-19	CDC6 association with the ORC:origin complex, and Double-strand break repair via break-induced replication
Process	102	4.350000000000001e-21	7.41e-19	Regulation of nucleobase-containing compound metabolic process
HPO	33	7.83e-21	8.38e-19	Abnormal leukocyte count
HPO	22	8.28e-21	8.78e-19	Abnormality of the phalanges of the toes
HPO	26	8.52e-21	8.96e-19	Functional abnormality of male internal genitalia
WikiPathways	17	1.99e-20	1.04e-18	Integrated cancer pathway
HPO	23	1.03e-20	1.05e-18	Abnormal ureter morphology
HPO	26	1.22e-20	1.24e-18	Limb undergrowth
Process	26	8.52e-21	1.44e-18	Meiotic cell cycle process
Process	23	8.8e-21	1.47e-18	Meiosis I cell cycle process
Process	48	9.3e-21	1.54e-18	Nucleobase-containing compound biosynthetic process
HPO	46	1.56e-20	1.56e-18	Abnormal mandible morphology
HPO	24	2.07e-20	2.05e-18	Abnormal esophagus morphology
COMPARTMENTS	19	3.56e-20	2.34e-18	Chromosome, telomeric region
Process	14	1.55e-20	2.53e-18	DNA replication checkpoint signaling
Process	18	1.71e-20	2.76e-18	Response to gamma radiation
HPO	25	3.55e-20	3.49e-18	Abnormality of the anus
HPO	43	3.64e-20	3.55e-18	Localized skin lesion
Process	18	2.24e-20	3.58e-18	Reciprocal meiotic recombination
Keyword	23	6.09e-20	3.97e-18	Helicase
Keyword	57	5.91e-20	3.97e-18	ATP-binding
HPO	27	4.12e-20	3.99e-18	Abnormality of the spinal cord
RCTM	13	1.28e-19	4.23e-18	Removal of the Flap Intermediate
DISEASES	55	5.610000000000001e-21	4.3e-18	Syndrome
HPO	33	4.75e-20	4.56e-18	Abnormal internal genitalia
HPO	39	4.81e-20	4.59e-18	Abnormal penis morphology
Function	60	1.63e-20	4.74e-18	ATP binding
RCTM	14	2.12e-19	6.91e-18	E2F mediated regulation of DNA replication
HPO	18	8.12e-20	7.68e-18	Melanoma
Component	13	1.28e-19	8.43e-18	Fanconi anaemia nuclear complex
COMPARTMENTS	18	1.68e-19	1.07e-17	Site of double-strand break
HPO	39	1.59e-19	1.49e-17	Aplasia/hypoplasia of the extremities
HPO	40	1.63e-19	1.51e-17	Abnormality of the lower urinary tract
HPO	38	1.75e-19	1.6e-17	Aplasia/hypoplasia involving bones of the extremities
HPO	48	1.84e-19	1.68e-17	Aplasia/hypoplasia involving the skeleton
HPO	39	1.87e-19	1.69e-17	Cleft palate
Process	22	1.1e-19	1.73e-17	Meiosis I
RCTM	17	5.91e-19	1.9e-17	Meiotic recombination
HPO	33	2.24e-19	2.01e-17	Reduced bone mineral density
HPO	21	2.49e-19	2.22e-17	Abnormality of enteric ganglion morphology
HPO	21	2.49e-19	2.22e-17	Aganglionic megacolon
HPO	36	2.93e-19	2.53e-17	Abnormal cellular immune system morphology
HPO	36	2.93e-19	2.53e-17	Abnormal leukocyte morphology
HPO	22	3.1e-19	2.65e-17	Decreased fertility in males
HPO	21	4.02e-19	3.4e-17	Abnormal aortic valve morphology
NetworkNeighborAL	13	1.28e-19	3.44e-17	DNA polymerase complex
RCTM	19	1.16e-18	3.68e-17	Meiosis
Process	22	2.69e-19	4.09e-17	Regulation of DNA recombination
HPO	49	4.98e-19	4.19e-17	Abnormal facial skeleton morphology
HPO	28	5.66e-19	4.73e-17	Abnormal tracheobronchial morphology
HPO	39	5.88e-19	4.88e-17	Abnormal bone structure
HPO	23	5.96e-19	4.92e-17	Dolichocephaly
HPO	27	6.49e-19	5.31e-17	Abnormality of femur morphology
RCTM	12	1.85e-18	5.8e-17	HDR through MMEJ (alt-NHEJ)
RCTM	12	1.85e-18	5.8e-17	Unwinding of DNA
HPO	70	7.22e-19	5.83e-17	Growth abnormality
HPO	22	7.23e-19	5.83e-17	Oligohydramnios
RCTM	13	2.12e-18	6.44e-17	Processive synthesis on the C-strand of the telomere
HPO	63	8.68e-19	6.92e-17	Abnormal cerebral morphology
HPO	27	9.37e-19	7.42e-17	Ocular anterior segment dysgenesis
Keyword	73	1.64e-18	9.21e-17	Ubl conjugation
Process	27	6.49e-19	9.78e-17	Regulation of chromosome organization
Component	12	1.85e-18	1.19e-16	DNA replication preinitiation complex
Function	70	5.13e-19	1.26e-16	Nucleotide binding
NetworkNeighborAL	15	5.18e-19	1.32e-16	Defective binding of RB1 mutants to E2F1,(E2F2, E2F3), and Cyclin-dependent protein serine/threonine kinase regulator activity
HPO	24	1.72e-18	1.34e-16	Anemia (phenotype)
HPO	44	2.11e-18	1.62e-16	Abnormal hand morphology
Function	15	7.41e-19	1.66e-16	Endodeoxyribonuclease activity
Process	29	1.12e-18	1.67e-16	Response to light stimulus
SMART	14	2.12e-19	1.74e-16	Breast cancer carboxy-terminal domain
HPO	27	2.29e-18	1.74e-16	Abnormal size of the palpebral fissures
HPO	21	2.42e-18	1.82e-16	Tetralogy of Fallot
RCTM	12	6.51e-18	1.95e-16	Polymerase switching
HPO	30	2.67e-18	2e-16	Abnormal morphology of female internal genitalia
Process	21	1.36e-18	2.01e-16	Regulation of DNA biosynthetic process
Component	12	3.53e-18	2.19e-16	Nuclear replisome
COMPARTMENTS	12	3.53e-18	2.2e-16	MCM complex
Process	12	1.85e-18	2.72e-16	Double-strand break repair via break-induced replication
Function	116	1.29e-18	2.78e-16	Catalytic activity
RCTM	15	9.67e-18	2.83e-16	Formation of Incision Complex in GG-NER
HPO	17	4e-18	2.96e-16	Neoplasm of the breast
HPO	48	4.56e-18	3.35e-16	Abnormality of the endocrine system
Process	23	2.91e-18	4.23e-16	Meiotic nuclear division
InterPro	46	6.18e-20	4.44e-16	P-loop containing nucleoside triphosphate hydrolase
InterPro	20	6.95e-20	4.44e-16	Nucleic acid-binding, OB-fold
NetworkNeighborAL	12	1.85e-18	4.46e-16	Resolution of recombination intermediates, and Response to intra-S DNA damage checkpoint signaling
HPO	23	6.5e-18	4.75e-16	Finger syndactyly
Component	57	8.06e-18	4.85e-16	Catalytic complex
HPO	25	7.79e-18	5.62e-16	Umbilical hernia
HPO	24	8.48e-18	6.09e-16	Abnormality of the small intestine
HPO	54	8.6e-18	6.14e-16	Abnormality of the gastrointestinal tract
HPO	26	1.01e-17	7.15e-16	Abnormality of the ureter
HPO	24	1.04e-17	7.33e-16	Toe syndactyly
Process	16	5.49e-18	7.9e-16	Somatic diversification of immune receptors
NetworkNeighborAL	12	3.53e-18	8.08e-16	ATR signaling, and Mitotic DNA replication checkpoint signaling
HPO	28	1.16e-17	8.16e-16	Aplasia/Hypoplasia of fingers
HPO	29	1.17e-17	8.17e-16	Hydrocephalus
HPO	26	1.2e-17	8.32e-16	Upslanted palpebral fissure
COMPARTMENTS	30	1.64e-17	9.93e-16	Nuclear body
Process	15	7.19e-18	1.02e-15	DNA synthesis involved in DNA repair
HPO	25	1.5e-17	1.03e-15	Abnormal umbilicus morphology
HPO	69	1.63e-17	1.12e-15	Abnormality of brain morphology
HPO	35	2.12e-17	1.44e-15	Abnormal bone ossification
HPO	24	2.54e-17	1.72e-15	Proptosis
HPO	24	2.54e-17	1.72e-15	Hip dislocation
Process	14	1.23e-17	1.73e-15	Negative regulation of DNA replication
Keyword	22	3.43e-17	1.77e-15	Dwarfism
HPO	50	2.66e-17	1.78e-15	Abnormal ocular adnexa morphology
HPO	45	2.71e-17	1.81e-15	Abnormality of finger
HPO	39	2.92e-17	1.93e-15	Recurrent infections
InterPro	14	8.2e-19	1.96e-15	BRCT domain superfamily
Function	36	1.17e-17	2.41e-15	Chromatin binding
HPO	71	3.82e-17	2.52e-15	Morphological central nervous system abnormality
Keyword	31	5.56e-17	2.67e-15	Chromosome
HPO	28	4.12e-17	2.7e-15	Abnormal breast morphology
HPO	33	4.25e-17	2.77e-15	Anemia
Component	11	5.13e-17	3e-15	Nucleotide-excision repair complex
Component	11	5.13e-17	3e-15	CMG complex
COMPARTMENTS	11	5.13e-17	3.03e-15	CMG complex
HPO	43	4.86e-17	3.12e-15	Abnormal joint morphology
COMPARTMENTS	20	5.62e-17	3.23e-15	Serine/threonine protein kinase complex
HPO	27	5.1e-17	3.26e-15	Thrombocytopenia
KEGG	11	9.75e-17	3.64e-15	Non-homologous end-joining
HPO	67	5.95e-17	3.78e-15	Abnormality of the genitourinary system
HPO	19	6.12e-17	3.87e-15	Aplasia/Hypoplasia of the thumb
Process	116	2.83e-17	3.92e-15	Regulation of nitrogen compound metabolic process
HPO	52	6.34e-17	3.99e-15	Abnormality of immune system physiology
HPO	63	6.47e-17	4.05e-15	Abnormal skull morphology
COMPARTMENTS	24	7.87e-17	4.42e-15	Chromosomal region
HPO	73	7.23e-17	4.5e-15	Abnormal skeletal morphology
Process	12	3.4e-17	4.68e-15	Mitotic intra-S DNA damage checkpoint signaling
HPO	54	7.87e-17	4.87e-15	Abnormality of limb bone morphology
Function	182	2.51e-17	4.95e-15	Binding
HPO	75	8.08e-17	4.96e-15	Abnormality of the skeletal system
TISSUES	48	4.1e-18	4.97e-15	Leukemia cell
HPO	67	8.73e-17	5.33e-15	Abnormal axial skeleton morphology
HPO	39	9.45e-17	5.73e-15	Unusual infection
DISEASES	78	1.01e-17	5.82e-15	Autosomal genetic disease
HPO	54	1.08e-16	6.47e-15	Abnormality of the nose
HPO	45	1.1e-16	6.59e-15	Abnormal pinna morphology
Process	112	4.98e-17	6.79e-15	Cellular component organization
Function	28	4.43e-17	8.4e-15	ATP hydrolysis activity
WikiPathways	11	1.79e-16	8.71e-15	Homologous recombination
HPO	72	1.56e-16	9.24e-15	Abnormal nervous system morphology
HPO	28	1.56e-16	9.24e-15	Syndactyly
HPO	20	1.58e-16	9.25e-15	Abnormality of multiple cell lineages in the bone marrow
HPO	21	1.6e-16	9.37e-15	Abnormality of bone marrow cell morphology
Process	17	7.07e-17	9.56e-15	Protein monoubiquitination
NetworkNeighborAL	11	5.13e-17	1.07e-14	Nonhomologous end joining complex
HPO	27	1.93e-16	1.11e-14	Abnormal platelet count
NetworkNeighborAL	12	5.63e-17	1.12e-14	Nonhomologous end joining complex, and Mismatch repair complex
Process	55	9.21e-17	1.23e-14	Intracellular signal transduction
NetworkNeighborAL	13	6.84e-17	1.25e-14	Defective binding of RB1 mutants to E2F1,(E2F2, E2F3), and Phosphorylation of proteins involved in the G2/M transition by Cyclin A:Cdc2 complexes
Process	11	9.75e-17	1.3e-14	Mitotic DNA replication
HPO	24	2.3e-16	1.32e-14	Astigmatism
HPO	22	2.35e-16	1.35e-14	Abnormality of thumb phalanx
HPO	25	3.27e-16	1.85e-14	Cranial nerve paralysis
Process	22	1.4e-16	1.85e-14	Cell cycle phase transition
TISSUES	31	2.34e-17	1.89e-14	Lymphocytic leukemia cell
Process	12	1.44e-16	1.89e-14	Mitotic recombination
HPO	24	3.84e-16	2.16e-14	Decreased fertility
Keyword	19	4.88e-16	2.19e-14	Nuclease
WikiPathways	21	4.83e-16	2.22e-14	Primary ovarian insufficiency
Process	11	1.79e-16	2.31e-14	Positive regulation of DNA-directed DNA polymerase activity
InterPro	13	1.36e-17	2.44e-14	BRCT domain
Process	27	1.93e-16	2.46e-14	Nuclear division
HPO	25	4.49e-16	2.51e-14	Neoplasm by histology
Process	13	2.02e-16	2.56e-14	Mismatch repair
Process	14	2.06e-16	2.58e-14	Somatic diversification of immunoglobulins
RCTM	11	9.08e-16	2.59e-14	Translesion synthesis by REV1
WikiPathways	14	6.07e-16	2.63e-14	ATM signaling in development and disease 
HPO	49	5.2e-16	2.89e-14	Abnormal digit morphology
NetworkNeighborAL	16	1.69e-16	2.98e-14	Mixed, incl. G1 Phase, and G0 and Early G1
HPO	32	6.1e-16	3.35e-14	Aplasia/hypoplasia involving bones of the upper limbs
Process	116	2.76e-16	3.44e-14	Regulation of primary metabolic process
Process	13	2.85e-16	3.52e-14	Response to X-ray
HPO	56	6.84e-16	3.74e-14	Abnormality of skin morphology
Keyword	11	9.08e-16	3.81e-14	DNA-directed DNA polymerase
Process	11	3.16e-16	3.87e-14	Base-excision repair, gap-filling
Keyword	58	9.84e-16	3.89e-14	Nucleotide-binding
SMART	20	9.48e-17	3.89e-14	ATPases associated with a variety of cellular activities
RCTM	11	1.48e-15	4.18e-14	Translesion synthesis by POLK
RCTM	11	1.48e-15	4.18e-14	Removal of the Flap Intermediate from the C-strand
RCTM	11	1.48e-15	4.18e-14	Translesion synthesis by POLI
HPO	27	7.71e-16	4.2e-14	Abnormality of the peripheral nervous system
HPO	31	8.2e-16	4.43e-14	Aplasia/hypoplasia involving bones of the hand
HPO	40	8.2e-16	4.43e-14	Morphological abnormality of the gastrointestinal tract
HPO	56	8.61e-16	4.61e-14	Abnormality of the urinary system
HPO	26	8.96e-16	4.77e-14	Abnormality of the hypothalamus-pituitary axis
NetworkNeighborAL	13	2.85e-16	4.83e-14	Base excision repair, and DNA topological change
HPO	40	9.54e-16	5.06e-14	Abnormality of digestive system morphology
HPO	33	9.77e-16	5.12e-14	Abnormality of lower limb joint
WikiPathways	10	1.42e-15	5.84e-14	Non-homologous end joining
Process	11	5.43e-16	6.55e-14	Regulation of DNA-templated DNA replication initiation
HPO	18	1.27e-15	6.62e-14	Telangiectasia
HPO	53	1.28e-15	6.62e-14	Abnormality of the lower limb
HPO	49	1.3e-15	6.72e-14	Abnormality of connective tissue
Process	17	5.76e-16	6.9e-14	Cellular response to UV
Function	61	4.42e-16	7.78e-14	Purine nucleotide binding
COMPARTMENTS	10	1.42e-15	7.78e-14	GINS complex
Function	61	4.74e-16	8.07e-14	Ribonucleotide binding
HPO	25	1.63e-15	8.31e-14	Abnormal hip joint morphology
Process	13	7.52e-16	8.86e-14	Mitotic G2 DNA damage checkpoint signaling
HPO	24	1.8e-15	9.17e-14	Renal hypoplasia/aplasia
Process	13	1.02e-15	1.18e-13	Postreplication repair
HPO	26	2.53e-15	1.28e-13	Frontal bossing
TISSUES	49	2.15e-16	1.3e-13	Blood cancer cell
HPO	26	2.7e-15	1.36e-13	Abnormal shape of the frontal region
HPO	26	2.89e-15	1.45e-13	Abnormal thumb morphology
Process	54	1.31e-15	1.49e-13	Negative regulation of nucleobase-containing compound metabolic process
Function	11	9.08e-16	1.49e-13	DNA replication origin binding
Process	19	1.34e-15	1.51e-13	Regulation of double-strand break repair
HPO	59	3.52e-15	1.75e-13	Abnormality of the skin
HPO	42	3.55e-15	1.76e-13	Abnormal facial shape
HPO	71	3.75e-15	1.85e-13	Abnormality of the face
HPO	31	4.35e-15	2.13e-13	Abnormal pelvic girdle bone morphology
HPO	61	4.47e-15	2.17e-13	Abnormality of limbs
HPO	27	4.67e-15	2.26e-13	Hernia of the abdominal wall
HPO	35	4.77e-15	2.3e-13	Abnormal intestine morphology
NetworkNeighborAL	10	1.42e-15	2.32e-13	CMG complex, and Replication fork arrest
HPO	22	5.14e-15	2.47e-13	Abnormality of the autonomic nervous system
HPO	14	5.2e-15	2.49e-13	Breast carcinoma
HPO	34	5.5e-15	2.62e-13	High palate
HPO	27	5.96e-15	2.83e-13	Abdominal wall defect
HPO	35	6.4e-15	3.03e-13	Abnormality of the palpebral fissures
HPO	55	6.58e-15	3.1e-13	Abnormality of the immune system
HPO	33	6.73e-15	3.16e-13	Slanting of the palpebral fissure
Function	18	2.19e-15	3.27e-13	Nucleotidyltransferase activity
RCTM	17	1.27e-14	3.45e-13	Assembly of the pre-replicative complex
HPO	34	7.46e-15	3.49e-13	Cataract
WikiPathways	17	9.71e-15	3.79e-13	Androgen receptor network in prostate cancer
RCTM	10	1.46e-14	3.91e-13	Mismatch repair (MMR) directed by MSH2:MSH3 (MutSbeta)
HPO	24	8.73e-15	4.06e-13	Renal insufficiency
HPO	43	1e-14	4.65e-13	Abnormal eyelid morphology
Function	18	3.24e-15	4.7e-13	Endonuclease activity
RCTM	14	1.82e-14	4.84e-13	DNA Damage/Telomere Stress Induced Senescence
HPO	30	1.11e-14	5.14e-13	Abnormal cerebrospinal fluid morphology
HPO	23	1.15e-14	5.28e-13	Abnormal heart valve morphology
Process	10	4.89e-15	5.47e-13	T-circle formation
HPO	43	1.33e-14	6.11e-13	Abnormal respiratory system morphology
Process	13	5.57e-15	6.11e-13	Somatic diversification of immune receptors via germline recombination within a single locus
HPO	29	1.45e-14	6.61e-13	Abnormal hip bone morphology
DISEASES	15	1.3e-15	6.62e-13	Breast cancer
RCTM	14	2.7e-14	7.01e-13	TP53 Regulates Transcription of DNA Repair Genes
HPO	64	1.68e-14	7.63e-13	Abnormality of the integument
Process	20	7.1e-15	7.68e-13	Mitotic cell cycle phase transition
NetworkNeighborAL	10	4.89e-15	7.71e-13	BRCA1-C complex, and NIPBL role in DNA damage - Cornelia de Lange syndrome
HPO	21	1.71e-14	7.74e-13	Abnormal ventriculoarterial connection
Process	16	7.24e-15	7.77e-13	Cell cycle G1/S phase transition
Keyword	80	2.28e-14	8.53e-13	Acetylation
NetworkNeighborAL	11	5.7e-15	8.69e-13	Base excision repair
HPO	73	1.98e-14	8.88e-13	Abnormality of the head
Process	117	8.4e-15	8.96e-13	Regulation of macromolecule metabolic process
TISSUES	39	2.01e-15	9.74e-13	Embryo
HPO	42	2.29e-14	1.02e-12	Abnormal palate morphology
HPO	27	2.31e-14	1.03e-12	Abnormal systemic arterial morphology
Process	15	1.06e-14	1.12e-12	Positive regulation of DNA biosynthetic process
HPO	28	2.51e-14	1.12e-12	Hernia
HPO	29	2.69e-14	1.19e-12	External genital hypoplasia
HPO	34	2.74e-14	1.2e-12	Abnormal cornea morphology
HPO	27	2.74e-14	1.2e-12	Abnormal upper limb bone morphology
WikiPathways	9	3.93e-14	1.46e-12	ATR signaling
Process	110	1.39e-14	1.46e-12	Regulation of cellular metabolic process
TISSUES	22	4.33e-15	1.75e-12	Pronephros
Function	11	1.28e-14	1.8e-12	DNA damage sensor activity
HPO	47	4.19e-14	1.82e-12	Abnormality of the hand
HPO	24	4.28e-14	1.86e-12	Pes planus
InterPro	10	1.42e-15	2.04e-12	MCM domain
InterPro	10	1.42e-15	2.04e-12	Mini-chromosome maintenance protein
InterPro	10	1.42e-15	2.04e-12	MCM, AAA-lid domain
COMPARTMENTS	9	3.93e-14	2.05e-12	DNA-dependent protein kinase complex
Keyword	54	5.93e-14	2.1e-12	Isopeptide bond
DISEASES	80	4.6e-15	2.11e-12	Monogenic disease
NetworkNeighborAL	10	1.46e-14	2.15e-12	APEX1-Independent Resolution of AP Sites via the Single Nucleotide Replacement Pathway, and PNK, FHA domain
Component	9	3.93e-14	2.17e-12	Nonhomologous end joining complex
HPO	23	5.33e-14	2.31e-12	Delayed skeletal maturation
Process	10	2.41e-14	2.52e-12	Negative regulation of DNA-templated DNA replication
HPO	10	6.1e-14	2.62e-12	Abnormality of DNA repair
HPO	28	6.15e-14	2.63e-12	Hypoplastic male external genitalia
RCTM	11	1.05e-13	2.7e-12	G1/S-Specific Transcription
HPO	28	6.47e-14	2.76e-12	Cardiomyopathy
Function	15	2.11e-14	2.89e-12	Exonuclease activity
HPO	57	7.12e-14	3.03e-12	Cognitive impairment
HPO	9	7.4e-14	3.13e-12	Chromosomal breakage induced by crosslinking agents
HPO	24	7.7e-14	3.25e-12	Abnormality of the curvature of the cornea
HPO	51	8.33e-14	3.51e-12	Global developmental delay
HPO	25	8.68e-14	3.64e-12	Abnormality iris morphology
Process	11	3.87e-14	3.99e-12	Translesion synthesis
HPO	39	9.64e-14	4.03e-12	Abnormal conjugate eye movement
Process	15	5.59e-14	5.73e-12	Negative regulation of response to DNA damage stimulus
Process	30	5.81e-14	5.92e-12	Cell division
HPO	45	1.52e-13	6.3e-12	Abnormal foot morphology
Process	16	6.43e-14	6.51e-12	Regulation of telomere maintenance
Process	12	6.63e-14	6.66e-12	Negative regulation of telomere maintenance
Function	12	5.08e-14	6.77e-12	Telomeric DNA binding
COMPARTMENTS	9	1.33e-13	6.82e-12	Origin recognition complex
HPO	38	1.68e-13	6.93e-12	Strabismus
HPO	64	1.85e-13	7.64e-12	Abnormality of the digestive system
Process	23	8.08e-14	8.07e-12	Chromosome segregation
HPO	48	1.98e-13	8.13e-12	Abnormality of the upper limb
HPO	52	2.12e-13	8.69e-12	Intellectual disability
RCTM	18	3.43e-13	8.7e-12	Cellular Senescence
Process	15	8.87e-14	8.8e-12	G1/S transition of mitotic cell cycle
HPO	46	2.17e-13	8.85e-12	Abnormal ear morphology
HPO	44	2.22e-13	9.02e-12	Abnormality of blood and blood-forming tissues
HPO	21	2.45e-13	9.95e-12	Hypertrophic cardiomyopathy
HPO	56	2.49e-13	1.01e-11	Abnormal oral cavity morphology
HPO	46	2.6e-13	1.04e-11	Hearing abnormality
COMPARTMENTS	10	2.12e-13	1.06e-11	DNA recombinase mediator complex
HPO	14	2.68e-13	1.07e-11	Cutaneous photosensitivity
HPO	12	2.89e-13	1.15e-11	Absent thumb
HPO	52	3.13e-13	1.24e-11	Abnormality of the vasculature
Keyword	14	3.68e-13	1.24e-11	Endonuclease
Process	59	1.36e-13	1.35e-11	Positive regulation of nucleobase-containing compound metabolic process
HPO	75	3.42e-13	1.36e-11	Abnormality of the musculoskeletal system
HPO	38	3.53e-13	1.39e-11	Abnormality of the forehead
HPO	21	3.55e-13	1.4e-11	Patent ductus arteriosus
Process	11	1.44e-13	1.41e-11	Cellular response to gamma radiation
HPO	45	3.86e-13	1.51e-11	Hearing impairment
HPO	79	4e-13	1.56e-11	Abnormality of the nervous system
Process	14	1.63e-13	1.59e-11	Regulation of double-strand break repair via homologous recombination
RCTM	9	6.32e-13	1.59e-11	Mismatch repair (MMR) directed by MSH2:MSH6 (MutSalpha)
Keyword	25	5.39e-13	1.72e-11	Cell division
HPO	57	4.63e-13	1.8e-11	Abnormality of the mouth
Process	10	2.12e-13	2.05e-11	DNA double-strand break processing
Component	36	3.8e-13	2.05e-11	Nuclear body
HPO	44	6.16e-13	2.39e-11	Abnormality of the vertebral column
HPO	46	6.36e-13	2.46e-11	Abnormal ear physiology
Process	11	2.62e-13	2.52e-11	Somatic recombination of immunoglobulin gene segments
HPO	24	6.8e-13	2.63e-11	Atrial septal defect
RCTM	8	1.09e-12	2.7e-11	CDC6 association with the ORC:origin complex
RCTM	8	1.09e-12	2.7e-11	DNA replication initiation
HPO	30	8.47e-13	3.25e-11	Abnormality of toe
Process	47	3.55e-13	3.4e-11	Macromolecule biosynthetic process
HPO	34	8.91e-13	3.41e-11	Abnormal cerebral ventricle morphology
Component	39	6.73e-13	3.53e-11	Nucleolus
InterPro	9	3.93e-14	3.53e-11	MCM OB domain
WikiPathways	9	1e-12	3.56e-11	miRNAs involved in DNA damage response
HPO	22	9.81e-13	3.74e-11	Abnormal aortic morphology
HPO	23	1.1e-12	4.18e-11	Abnormality of skeletal maturation
NetworkNeighborAL	10	3.1e-13	4.43e-11	Defective binding of RB1 mutants to E2F1,(E2F2, E2F3), and Cyclin-dependent protein serine/threonine kinase inhibitor activity
Process	15	4.85e-13	4.61e-11	Meiotic chromosome segregation
RCTM	8	2.04e-12	4.94e-11	E2F-enabled inhibition of pre-replication complex formation
DISEASES	10	1.42e-13	5.03e-11	Retinal cancer
HPO	61	1.35e-12	5.13e-11	Abnormality of higher mental function
COMPARTMENTS	8	1.09e-12	5.32e-11	DNA replication factor A complex
RCTM	10	2.31e-12	5.55e-11	G0 and Early G1
Component	8	1.09e-12	5.56e-11	MCM complex
HPO	55	1.49e-12	5.61e-11	Neurodevelopmental delay
Process	9	6.32e-13	5.97e-11	Telomere maintenance via recombination
HPO	26	1.59e-12	5.99e-11	Abnormal uvea morphology
HPO	38	1.6e-12	6.02e-11	Abnormality of the curvature of the vertebral column
Keyword	13	2.06e-12	6.3e-11	Nucleotidyltransferase
HPO	50	1.88e-12	7.03e-11	Abnormality of the respiratory system
HPO	26	2.02e-12	7.55e-11	Epicanthus
HPO	61	2.02e-12	7.55e-11	Neurodevelopmental abnormality
HPO	57	2.49e-12	9.22e-11	Abnormal eye morphology
KEGG	13	2.83e-12	9.5e-11	p53 signaling pathway
Process	14	1.06e-12	9.87e-11	Negative regulation of chromosome organization
HPO	14	2.8e-12	1.03e-10	Short thumb
HPO	12	2.82e-12	1.04e-10	Telangiectasia of the skin
Component	15	2.19e-12	1.09e-10	Serine/threonine protein kinase complex
Function	10	8.92e-13	1.12e-10	Exodeoxyribonuclease activity, producing 5-phosphomonoesters
Keyword	49	4.03e-12	1.18e-10	Hydrolase
RCTM	9	5.12e-12	1.22e-10	Translesion Synthesis by POLH
HPO	9	3.5e-12	1.29e-10	Poikiloderma
HPO	47	3.63e-12	1.33e-10	Abnormality of eye movement
HPO	8	3.63e-12	1.33e-10	Microtia, third degree
Process	15	1.53e-12	1.42e-10	Positive regulation of chromosome organization
Process	9	1.55e-12	1.43e-10	Replicative senescence
NetworkNeighborAL	8	1.09e-12	1.51e-10	DNA replication initiation
HPO	54	4.45e-12	1.62e-10	Abnormality of the ear
COMPARTMENTS	8	3.63e-12	1.74e-10	XPC complex
HPO	62	4.83e-12	1.76e-10	Abnormality of the cardiovascular system
HPO	39	5.35e-12	1.94e-10	Abnormality of the abdominal organs
HPO	8	6.22e-12	2.25e-10	Anotia
HPO	28	7.09e-12	2.55e-10	Abnormal cardiac septum morphology
HPO	9	7.35e-12	2.64e-10	Patellar aplasia
InterPro	17	3.53e-13	2.82e-10	AAA+ ATPase domain
HPO	36	8.97e-12	3.21e-10	Abnormality of the urinary system physiology
Process	8	3.63e-12	3.33e-10	DNA ligation
HPO	36	9.8e-12	3.5e-10	Nystagmus
Function	61	3.12e-12	3.66e-10	Hydrolase activity
Process	10	4.14e-12	3.78e-10	Chromosome separation
HPO	16	1.19e-11	4.24e-10	Craniosynostosis
DISEASES	82	1.39e-12	4.25e-10	Genetic disease
HPO	36	1.2e-11	4.26e-10	Abnormal involuntary eye movements
HPO	38	1.22e-11	4.31e-10	Abnormal reflex
Process	47	4.88e-12	4.4e-10	Reproductive process
COMPARTMENTS	29	9.41e-12	4.42e-10	Nucleolus
DISEASES	9	1.55e-12	4.46e-10	Retinoblastoma
HPO	39	1.3e-11	4.6e-10	Abnormality of the upper urinary tract
DISEASES	15	1.94e-12	4.96e-10	Ovarian disease
Process	17	5.76e-12	5.16e-10	Positive regulation of response to DNA damage stimulus
HPO	39	1.49e-11	5.21e-10	Abnormal anterior eye segment morphology
Function	9	5.12e-12	5.87e-10	ATP-dependent DNA damage sensor activity
RCTM	8	2.57e-11	6.04e-10	TP53 Regulates Transcription of Genes Involved in G1 Cell Cycle Arrest
Function	10	5.47e-12	6.14e-10	DNA secondary structure binding
COMPARTMENTS	11	1.47e-11	6.78e-10	Cyclin-dependent protein kinase holoenzyme complex
DISEASES	12	2.82e-12	6.82e-10	Ovarian cancer
Process	19	7.91e-12	7.01e-10	Nuclear chromosome segregation
HPO	71	2.07e-11	7.2e-10	Abnormal nervous system physiology
Process	72	8.48e-12	7.47e-10	Positive regulation of nitrogen compound metabolic process
HPO	67	2.3e-11	7.99e-10	Abnormality of the eye
DISEASES	8	3.63e-12	8.35e-10	Xeroderma pigmentosum group G
Function	61	8.48e-12	9.3e-10	Anion binding
DISEASES	18	4.37e-12	9.57e-10	Female reproductive system disease
Component	20	2.03e-11	9.66e-10	Condensed chromosome
HPO	38	2.8e-11	9.7e-10	Abnormality of the kidney
Process	92	1.4e-11	1.23e-09	Negative regulation of cellular process
DISEASES	8	6.22e-12	1.24e-09	Meier-Gorlin syndrome
DISEASES	26	6.75e-12	1.29e-09	Hematopoietic system disease
HPO	8	3.9e-11	1.34e-09	Breast aplasia
HPO	10	3.94e-11	1.35e-09	Freckling
HPO	24	3.94e-11	1.35e-09	Vascular skin abnormality
COMPARTMENTS	7	3.02e-11	1.36e-09	BRCA1-C complex
COMPARTMENTS	7	3.02e-11	1.36e-09	ERCC4-ERCC1 complex
COMPARTMENTS	7	3.02e-11	1.36e-09	DNA ligase IV complex
HPO	32	4.06e-11	1.39e-09	Abnormality of prenatal development or birth
HPO	11	4.47e-11	1.52e-09	Bone marrow hypocellularity
HPO	33	4.62e-11	1.57e-09	Abnormality of globe location
DISEASES	14	8.8e-12	1.62e-09	Female reproductive organ cancer
RCTM	8	8.45e-11	1.97e-09	Defective binding of RB1 mutants to E2F1,(E2F2, E2F3)
WikiPathways	15	7.27e-11	2.47e-09	Male infertility
HPO	11	7.46e-11	2.53e-09	Squamous cell carcinoma
HPO	34	8.03e-11	2.71e-09	Scoliosis
HPO	59	8.17e-11	2.75e-09	Abnormal eye physiology
RCTM	11	1.21e-10	2.77e-09	Recruitment and ATM-mediated phosphorylation of repair and signaling proteins at DNA double strand breaks
Process	19	3.48e-11	3.03e-09	Positive regulation of cell cycle process
NetworkNeighborAL	8	2.57e-11	3.45e-09	Mixed, incl. Xeroderma pigmentosum variant type, and Rad18-like CCHC zinc finger
Function	35	3.55e-11	3.8e-09	Transferase activity, transferring phosphorus-containing groups
Component	41	8.22e-11	3.82e-09	Chromatin
NetworkNeighborAL	7	3.02e-11	3.94e-09	Fanconi anaemia nuclear complex
NetworkNeighborAL	7	3.02e-11	3.94e-09	CDC6 association with the ORC:origin complex
NetworkNeighborAL	7	3.02e-11	3.94e-09	RecQ family helicase-topoisomerase III complex, and RQC domain
HPO	8	1.21e-10	4.06e-09	Entropion
Process	14	4.82e-11	4.17e-09	Positive regulation of cell cycle phase transition
COMPARTMENTS	7	9.88e-11	4.21e-09	Pre-replicative complex
COMPARTMENTS	12	1.05e-10	4.41e-09	PML body
HPO	55	1.33e-10	4.46e-09	Abnormality of metabolism/homeostasis
Component	7	9.88e-11	4.5e-09	Nuclear origin of replication recognition complex
HPO	13	1.44e-10	4.79e-09	Pancytopenia
Process	7	5.61e-11	4.83e-09	Negative regulation of telomere capping
Process	7	5.61e-11	4.83e-09	Nucleotide-excision repair, DNA incision
DISEASES	7	3.02e-11	5.13e-09	Hereditary breast ovarian cancer syndrome
RCTM	10	2.4e-10	5.38e-09	Cyclin D associated events in G1
WikiPathways	15	1.73e-10	5.64e-09	Breast cancer pathway
WikiPathways	12	1.77e-10	5.64e-09	Glioblastoma signaling pathways
HPO	32	1.89e-10	6.28e-09	Abnormal renal morphology
HPO	28	1.91e-10	6.35e-09	Hyperreflexia
RCTM	11	3.01e-10	6.6e-09	G1/S DNA Damage Checkpoints
WikiPathways	12	2.28e-10	6.84e-09	Pyrimidine metabolism
RCTM	10	3.44e-10	7.48e-09	TP53 Regulates Transcription of Cell Cycle Genes
HPO	26	2.3e-10	7.61e-09	Abnormal renal physiology
HPO	33	2.33e-10	7.67e-09	Abnormality of the liver
Component	12	1.77e-10	7.72e-09	Condensed nuclear chromosome
WikiPathways	7	2.7e-10	7.82e-09	SMC1/SMC3 role in DNA damage - Cornelia de Lange Syndrome
HPO	34	2.48e-10	8.15e-09	Failure to thrive
Process	7	9.88e-11	8.42e-09	Replication fork protection
HPO	27	2.97e-10	9.74e-09	Ventriculomegaly
Process	8	1.21e-10	1.03e-08	Resolution of meiotic recombination intermediates
HPO	8	3.24e-10	1.06e-08	Conjunctival telangiectasia
Keyword	10	4.09e-10	1.15e-08	Exonuclease
Process	10	1.37e-10	1.15e-08	Negative regulation of DNA recombination
HPO	14	3.68e-10	1.2e-08	Dry skin
DISEASES	31	7.39e-11	1.21e-08	Organ system cancer
RCTM	9	5.66e-10	1.22e-08	Aberrant regulation of mitotic cell cycle due to RB1 defects
Process	42	1.64e-10	1.38e-08	Regulation of response to stress
Process	7	1.67e-10	1.39e-08	Mitotic DNA replication checkpoint signaling
Process	7	1.67e-10	1.39e-08	Error-prone translesion synthesis
Process	21	1.72e-10	1.42e-08	Positive regulation of cell cycle
Process	74	1.85e-10	1.52e-08	Positive regulation of macromolecule metabolic process
HPO	21	4.94e-10	1.61e-08	Congenital malformation of the great arteries
HPO	31	5.04e-10	1.64e-08	Generalized abnormality of skin
Process	11	2.24e-10	1.83e-08	Regulation of telomere maintenance via telomere lengthening
NetworkNeighborAL	7	1.67e-10	2.01e-08	Nucleotide-excision repair complex, and XPG/Rad2 endonuclease, eukaryotes
NetworkNeighborAL	7	1.67e-10	2.01e-08	Defective binding of RB1 mutants to E2F1,(E2F2, E2F3)
Component	10	4.85e-10	2.07e-08	Cyclin-dependent protein kinase holoenzyme complex
Process	7	2.7e-10	2.2e-08	Telomeric loop disassembly
RCTM	29	1.06e-09	2.25e-08	Cellular responses to stress
Keyword	9	8.56e-10	2.3e-08	4Fe-4S
Function	8	2.37e-10	2.43e-08	DNA polymerase binding
HPO	6	8.4e-10	2.71e-08	Primary peritoneal carcinoma
HPO	37	8.42e-10	2.71e-08	Abnormality of vision
Process	11	3.47e-10	2.8e-08	Positive regulation of telomere maintenance
HPO	15	8.99e-10	2.89e-08	Neoplasm of the skin
Process	33	3.7e-10	2.98e-08	Regulation of transferase activity
Function	53	2.98e-10	3e-08	Enzyme binding
HPO	27	9.54e-10	3.06e-08	Ptosis
HPO	7	9.63e-10	3.07e-08	Mandibular aplasia
Function	104	3.26e-10	3.22e-08	Ion binding
HPO	27	1.05e-09	3.35e-08	Hypertelorism
Process	7	4.24e-10	3.39e-08	UV protection
COMPARTMENTS	6	8.4e-10	3.45e-08	Rad51B-Rad51C-Rad51D-XRCC2 complex
Component	6	8.4e-10	3.51e-08	BRCA1-C complex
Process	9	4.57e-10	3.62e-08	Negative regulation of DNA repair
InterPro	7	5.61e-11	4.03e-08	DNA recombination and repair protein Rad51-like, C-terminal
InterPro	7	5.61e-11	4.03e-08	DNA recombination and repair protein RecA-like, ATP-binding domain
Process	12	5.88e-10	4.63e-08	Positive regulation of mitotic cell cycle phase transition
KEGG	15	1.59e-09	4.86e-08	Viral carcinogenesis
RCTM	11	2.39e-09	4.95e-08	Cyclin E associated events during G1/S transition
InterPro	8	8.45e-11	5.06e-08	DNA/RNA polymerase superfamily
Process	55	6.6e-10	5.18e-08	Negative regulation of cellular metabolic process
RCTM	6	2.69e-09	5.52e-08	POLB-Dependent Long Patch Base Excision Repair
RCTM	11	3e-09	6.12e-08	Cyclin A:Cdk2-associated events at S phase entry
COMPARTMENTS	6	1.55e-09	6.25e-08	Slx1-Slx4 complex
HPO	10	1.97e-09	6.27e-08	Convex nasal ridge
Process	6	8.4e-10	6.56e-08	Resolution of recombination intermediates
Keyword	6	2.69e-09	6.94e-08	Xeroderma pigmentosum
HPO	16	2.4e-09	7.6e-08	Neoplasm of the gastrointestinal tract
Process	13	9.85e-10	7.65e-08	Positive regulation of mitotic cell cycle
Component	12	1.9e-09	7.8e-08	PML body
DISEASES	15	4.93e-10	7.81e-08	Reproductive organ cancer
Process	11	1.02e-09	7.86e-08	Intrinsic apoptotic signaling pathway in response to DNA damage
HPO	18	2.58e-09	8.17e-08	Abnormality of cranial sutures
HPO	6	2.69e-09	8.47e-08	Flat nasal alae
HPO	7	2.79e-09	8.78e-08	Aplastic clavicle
HPO	91	2.93e-09	9.19e-08	Phenotypic abnormality
NetworkNeighborAL	6	8.4e-10	9.61e-08	ATR signaling, and Meiotic DNA double-strand break processing involved in reciprocal meiotic recombination
NetworkNeighborAL	6	8.4e-10	9.61e-08	PNK, FHA domain, and Resolution of AP sites via the single-nucleotide replacement pathway
NetworkNeighborAL	6	8.4e-10	9.61e-08	BRCA1-C complex
NetworkNeighborAL	6	8.4e-10	9.61e-08	Double-strand break repair via break-induced replication
NetworkNeighborAL	6	8.4e-10	9.61e-08	DNA recombination and repair protein Rad51-like, C-terminal, and Rad52 family
HPO	31	3.1e-09	9.68e-08	Abnormality of refraction
Process	9	1.27e-09	9.75e-08	Positive regulation of DNA replication
HPO	9	3.14e-09	9.81e-08	Papilloma
HPO	9	3.14e-09	9.81e-08	Neoplasm of the eye
Process	8	1.31e-09	1e-07	Regulation of telomere capping
Process	8	1.31e-09	1e-07	Mitochondrial genome maintenance
COMPARTMENTS	6	2.69e-09	1.07e-07	Nuclear origin of replication recognition complex
COMPARTMENTS	6	2.69e-09	1.07e-07	PCNA complex
Process	94	1.43e-09	1.08e-07	Negative regulation of biological process
DISEASES	106	7.37e-10	1.13e-07	Disease
HPO	13	3.65e-09	1.13e-07	Prematurely aged appearance
Process	6	1.55e-09	1.17e-07	DNA strand resection involved in replication fork processing
HPO	29	3.81e-09	1.18e-07	Abnormal blood vessel morphology
WikiPathways	8	4.26e-09	1.19e-07	Gastric cancer network 2
HPO	7	3.85e-09	1.19e-07	Prostate cancer
HPO	7	3.85e-09	1.19e-07	Abnormal fallopian tube morphology
DISEASES	6	8.4e-10	1.25e-07	Xeroderma pigmentosum variant type
Function	6	1.55e-09	1.39e-07	Mismatch repair complex binding
HPO	11	4.68e-09	1.43e-07	Dermal atrophy
Process	56	1.95e-09	1.46e-07	Negative regulation of nitrogen compound metabolic process
HPO	12	4.98e-09	1.52e-07	Microtia
NetworkNeighborAL	6	1.55e-09	1.57e-07	DNA replication factor C complex, and PCNA-p21 complex
Function	29	1.79e-09	1.58e-07	Hydrolase activity, acting on ester bonds
HPO	14	5.37e-09	1.63e-07	Aplasia/Hypoplasia of the skin
HPO	13	5.46e-09	1.66e-07	Leukemia
HPO	20	5.73e-09	1.73e-07	Hypoplasia of penis
HPO	11	5.8e-09	1.75e-07	Lymphoma
Process	6	2.69e-09	2.01e-07	Double-strand break repair via synthesis-dependent strand annealing
DISEASES	19	1.42e-09	2.04e-07	Reproductive system disease
Process	7	2.79e-09	2.08e-07	Telomere capping
Process	7	2.79e-09	2.08e-07	Mitochondrial DNA metabolic process
KEGG	10	7.5e-09	2.1e-07	Platinum drug resistance
Function	6	2.69e-09	2.32e-07	Oxidized DNA binding
HPO	24	7.75e-09	2.33e-07	Abnormal morphology of the great vessels
KEGG	15	9.14e-09	2.36e-07	Human T-cell leukemia virus 1 infection
Function	15	2.94e-09	2.5e-07	Protein C-terminus binding
Process	8	3.42e-09	2.52e-07	Telomere maintenance via telomere lengthening
HPO	38	8.92e-09	2.68e-07	Abnormal musculoskeletal physiology
RCTM	10	1.37e-08	2.76e-07	SUMOylation of DNA damage response and repair proteins
Process	7	3.85e-09	2.82e-07	V(D)J recombination
HPO	17	9.48e-09	2.84e-07	Short finger
HPO	9	9.65e-09	2.88e-07	Neoplasm of the pancreas
HPO	9	9.65e-09	2.88e-07	Ovarian neoplasm
HPO	14	9.91e-09	2.94e-07	Neoplasm of the genitourinary tract
Process	8	4.26e-09	3.11e-07	Positive regulation of cell cycle G2/M phase transition
HPO	10	1.08e-08	3.2e-07	Elbow dislocation
Process	6	4.44e-09	3.22e-07	Telomeric D-loop disassembly
HPO	32	1.12e-08	3.32e-07	Visual impairment
HPO	11	1.18e-08	3.49e-07	Severe short stature
HPO	7	1.21e-08	3.55e-07	Hypoplastic labia minora
Process	65	4.91e-09	3.55e-07	Positive regulation of cellular metabolic process
Function	6	4.44e-09	3.71e-07	Flap endonuclease activity
Process	7	5.22e-09	3.75e-07	Negative regulation of double-strand break repair via homologous recombination
HPO	24	1.37e-08	4.03e-07	Abnormal finger phalanx morphology
HPO	15	1.38e-08	4.04e-07	Micropenis
HPO	8	1.42e-08	4.14e-07	High pitched voice
Process	9	6.08e-09	4.36e-07	Regulation of cell cycle checkpoint
HPO	7	1.56e-08	4.55e-07	Epispadias
Process	8	6.51e-09	4.64e-07	Negative regulation of double-strand break repair
InterPro	6	8.4e-10	4.64e-07	MCM N-terminal domain
InterPro	6	8.4e-10	4.64e-07	Mini-chromosome maintenance, conserved site
RCTM	6	2.33e-08	4.66e-07	Inhibition of replication initiation of damaged DNA by RB1/E2F1
RCTM	6	2.33e-08	4.66e-07	Telomere C-strand synthesis initiation
HPO	8	1.7e-08	4.95e-07	Abnormal male internal genitalia morphology
HPO	9	1.72e-08	4.98e-07	Cachexia
Process	11	7.15e-09	5.07e-07	Protein localization to chromosome
HPO	7	2e-08	5.78e-07	Clitoral hypoplasia
HPO	8	2.03e-08	5.85e-07	Hypoplasia of the radius
COMPARTMENTS	6	1.61e-08	6.06e-07	Endodeoxyribonuclease complex
TISSUES	22	1.83e-09	6.36e-07	Bone marrow cancer cell
Process	7	9.23e-09	6.49e-07	Blastocyst growth
RCTM	6	3.3e-08	6.49e-07	Early Phase of HIV Life Cycle
RCTM	13	3.34e-08	6.52e-07	SUMO E3 ligases SUMOylate target proteins
HPO	12	2.3e-08	6.59e-07	Proportionate short stature
HPO	44	2.32e-08	6.63e-07	Abnormality of movement
HPO	6	2.33e-08	6.65e-07	Defective DNA repair after ultraviolet radiation damage
Function	9	8.3e-09	6.82e-07	3-5 exonuclease activity
HPO	7	2.54e-08	7.23e-07	Absent radius
Process	6	1.08e-08	7.56e-07	Single strand break repair
TISSUES	16	2.55e-09	7.73e-07	Chronic lymphocytic leukemia cell
Function	6	1.08e-08	8.73e-07	3-5 DNA helicase activity
COMPARTMENTS	5	2.36e-08	8.76e-07	ATR-ATRIP complex
COMPARTMENTS	5	2.36e-08	8.76e-07	Alpha DNA polymerase:primase complex
COMPARTMENTS	5	2.36e-08	8.76e-07	Epsilon DNA polymerase complex
COMPARTMENTS	5	2.36e-08	8.76e-07	RecQ family helicase-topoisomerase III complex
HPO	6	3.3e-08	9.29e-07	Bird-like facies
HPO	6	3.3e-08	9.29e-07	Ankyloblepharon
RCTM	9	4.87e-08	9.42e-07	p53-Dependent G1 DNA Damage Response
Component	5	2.36e-08	9.47e-07	Epsilon DNA polymerase complex
Component	5	2.36e-08	9.47e-07	Alpha DNA polymerase:primase complex
DISEASES	6	7.04e-09	9.52e-07	Cockayne syndrome
DISEASES	32	7.56e-09	9.92e-07	Cancer
Keyword	16	4.39e-08	1.02e-06	Mitosis
Keyword	5	4.29e-08	1.02e-06	Cockayne syndrome
Keyword	23	4.27e-08	1.02e-06	Magnesium
Process	59	1.48e-08	1.03e-06	Negative regulation of macromolecule metabolic process
HPO	15	3.94e-08	1.11e-06	Abnormal granulocyte count
DISEASES	27	9.09e-09	1.15e-06	Physical disorder
DISEASES	20	8.98e-09	1.15e-06	Endocrine system disease
Keyword	22	5.78e-08	1.25e-06	Host-virus interaction
Process	12	1.96e-08	1.36e-06	Positive regulation of DNA repair
RCTM	5	7.3e-08	1.38e-06	APEX1-Independent Resolution of AP Sites via the Single Nucleotide Replacement Pathway
COMPARTMENTS	5	4.29e-08	1.5e-06	Dbf4-dependent protein kinase complex
COMPARTMENTS	5	4.29e-08	1.5e-06	Holliday junction resolvase complex
Process	5	2.36e-08	1.63e-06	DNA ligation involved in DNA repair
Process	5	2.36e-08	1.63e-06	Mitotic DNA replication initiation
Process	5	2.36e-08	1.63e-06	Positive regulation of DNA primase activity
WikiPathways	10	6.63e-08	1.79e-06	p53 transcriptional gene network
KEGG	10	8.02e-08	1.92e-06	Small cell lung cancer
HPO	15	6.94e-08	1.93e-06	Abnormal epiphysis morphology
Process	9	2.94e-08	1.97e-06	Cellular senescence
Process	13	2.92e-08	1.97e-06	Regulation of G1/S transition of mitotic cell cycle
HPO	8	7.35e-08	2.04e-06	Ectopic kidney
HPO	11	7.6e-08	2.1e-06	Genital neoplasm
HPO	31	7.91e-08	2.18e-06	Abnormal vascular morphology
Process	13	3.34e-08	2.23e-06	Intrinsic apoptotic signaling pathway
NetworkNeighborAL	5	2.36e-08	2.35e-06	Replication fork arrest, and GINS complex protein
NetworkNeighborAL	5	2.36e-08	2.35e-06	GINS complex, and Minichromosome  maintenance proteins
NetworkNeighborAL	5	2.36e-08	2.35e-06	Response to intra-S DNA damage checkpoint signaling, and Crossover junction endodeoxyribonuclease activity
NetworkNeighborAL	5	2.36e-08	2.35e-06	Nonhomologous end joining complex
NetworkNeighborAL	5	2.36e-08	2.35e-06	Xeroderma pigmentosum group A, and XFE progeroid syndrome
COMPARTMENTS	5	7.3e-08	2.47e-06	Ctf18 RFC-like complex
TISSUES	101	9.29e-09	2.5e-06	Female reproductive system
Process	18	3.85e-08	2.56e-06	Negative regulation of organelle organization
Process	7	3.99e-08	2.64e-06	Somatic diversification of immunoglobulins involved in immune response
Component	5	7.3e-08	2.82e-06	DNA recombinase mediator complex
Component	5	7.3e-08	2.82e-06	Ctf18 RFC-like complex
DISEASES	5	2.36e-08	2.85e-06	Ataxia telangiectasia
HPO	11	1.04e-07	2.86e-06	Abnormal conjunctiva morphology
RCTM	7	1.57e-07	2.94e-06	Transcriptional Regulation by E2F6
Function	8	3.98e-08	3.17e-06	4 iron, 4 sulfur cluster binding
Process	25	4.93e-08	3.25e-06	Protein ubiquitination
Process	7	4.94e-08	3.25e-06	Positive regulation of G2/M transition of mitotic cell cycle
Function	5	4.29e-08	3.36e-06	Four-way junction helicase activity
TISSUES	56	1.43e-08	3.46e-06	Organism form
RCTM	7	1.87e-07	3.47e-06	Regulation of TP53 Degradation
Function	6	4.58e-08	3.53e-06	Endodeoxyribonuclease activity, producing 5-phosphomonoesters
HPO	16	1.36e-07	3.74e-06	Sparse hair
HPO	12	1.37e-07	3.75e-06	Neutropenia
NetworkNeighborAL	5	4.29e-08	3.85e-06	Checkpoint clamp complex
DISEASES	33	3.33e-08	3.93e-06	Disease of cellular proliferation
Component	23	1.06e-07	3.94e-06	Centrosome
COMPARTMENTS	20	1.23e-07	4.1e-06	Centrosome
COMPARTMENTS	9	1.36e-07	4.47e-06	Condensed nuclear chromosome
Process	5	7.3e-08	4.77e-06	Telomere maintenance via semi-conservative replication
Process	5	7.3e-08	4.77e-06	Regulation of t-circle formation
Process	7	7.44e-08	4.82e-06	Negative regulation of telomere maintenance via telomere lengthening
Process	18	7.6e-08	4.88e-06	Response to oxidative stress
HPO	21	1.79e-07	4.88e-06	Short digit
DISEASES	5	4.29e-08	4.93e-06	Li-Fraumeni syndrome
DISEASES	5	4.29e-08	4.93e-06	Bloom syndrome
TISSUES	5	2.36e-08	5.21e-06	U2-OS cell
TISSUES	53	2.42e-08	5.21e-06	Embryonic structure
Function	5	7.3e-08	5.54e-06	Oxidized purine DNA binding
RCTM	7	3.06e-07	5.59e-06	Assembly of the ORC complex at the origin of replication
SMART	11	2.1e-08	5.73e-06	DEAD-like helicases superfamily
HPO	7	2.21e-07	6.01e-06	Hypoplastic labia majora
SMART	11	3.01e-08	6.18e-06	Helicase superfamily c-terminal domain
HPO	9	2.28e-07	6.18e-06	Opacification of the corneal stroma
RCTM	8	3.55e-07	6.44e-06	SCF(Skp2)-mediated degradation of p27/p21
HPO	8	2.47e-07	6.68e-06	Hypergonadotropic hypogonadism
HPO	13	2.56e-07	6.89e-06	Small for gestational age
TISSUES	103	3.74e-08	6.97e-06	Reproductive system
Process	7	1.09e-07	6.99e-06	Mitotic G1 DNA damage checkpoint signaling
HPO	33	2.62e-07	7.04e-06	Abnormal heart morphology
Process	5	1.18e-07	7.5e-06	Immunoglobulin V(D)J recombination
Process	160	1.38e-07	8.72e-06	Biological regulation
Function	5	1.18e-07	8.79e-06	Bubble DNA binding
Function	5	1.18e-07	8.79e-06	Single-stranded DNA endodeoxyribonuclease activity
Function	5	1.18e-07	8.79e-06	DNA/DNA annealing activity
Function	5	1.18e-07	8.79e-06	5-flap endonuclease activity
HPO	30	3.38e-07	9.07e-06	Abnormal hair morphology
Process	51	1.48e-07	9.34e-06	Cellular biosynthetic process
HPO	8	3.55e-07	9.51e-06	Slender long bone
HPO	8	3.55e-07	9.51e-06	Submucous cleft hard palate
HPO	32	3.77e-07	1e-05	Abnormality of skin adnexa morphology
TISSUES	183	5.95e-08	1.03e-05	Animal
HPO	14	4.05e-07	1.08e-05	Retrognathia
HPO	40	4.2e-07	1.11e-05	Abnormality of cardiovascular system morphology
InterPro	5	2.36e-08	1.13e-05	DNA clamp superfamily
Process	9	1.86e-07	1.16e-05	Chromosome organization involved in meiotic cell cycle
HPO	8	4.48e-07	1.18e-05	Keratitis
RCTM	4	6.72e-07	1.21e-05	Phosphorylation of proteins involved in G1/S transition by active Cyclin E:Cdk2 complexes
RCTM	4	6.72e-07	1.21e-05	Resolution of AP sites via the single-nucleotide replacement pathway
WikiPathways	9	4.87e-07	1.27e-05	Pancreatic adenocarcinoma pathway
HPO	11	4.92e-07	1.29e-05	Joint hyperflexibility
COMPARTMENTS	22	4.01e-07	1.3e-05	Microtubule organizing center
HPO	30	5.29e-07	1.39e-05	Abnormality of joint mobility
Process	22	2.25e-07	1.4e-05	Positive regulation of transferase activity
HPO	7	5.6e-07	1.46e-05	Atresia of the external auditory canal
Process	147	2.56e-07	1.58e-05	Regulation of cellular process
HPO	11	6.35e-07	1.65e-05	Inflammatory abnormality of the eye
Component	26	4.51e-07	1.65e-05	Microtubule organizing center
HPO	7	6.46e-07	1.68e-05	Blepharitis
HPO	4	6.72e-07	1.74e-05	Deficient excision of UV-induced pyrimidine dimers in DNA
HPO	4	6.72e-07	1.74e-05	Prolonged G2 phase of cell cycle
InterPro	5	4.29e-08	1.93e-05	DNA recombination and repair protein, RecA-like
HPO	8	7.73e-07	1.99e-05	Clitoral hypertrophy
DISEASES	82	1.89e-07	2.06e-05	Disease of anatomical entity
DISEASES	11	1.89e-07	2.06e-05	Nervous system cancer
RCTM	4	1.2e-06	2.12e-05	G2 Phase
COMPARTMENTS	4	6.72e-07	2.15e-05	BRCA1-B complex
COMPARTMENTS	4	6.72e-07	2.15e-05	Rad17 RFC-like complex
COMPARTMENTS	4	6.72e-07	2.15e-05	Replication fork protection complex
COMPARTMENTS	4	6.72e-07	2.15e-05	Zeta DNA polymerase complex
COMPARTMENTS	4	6.72e-07	2.15e-05	DNA-dependent protein kinase-DNA ligase 4 complex
HPO	7	8.51e-07	2.17e-05	Decreased adipose tissue
HPO	7	8.51e-07	2.17e-05	Abnormal labia majora morphology
HPO	10	9.05e-07	2.3e-05	High, narrow palate
Process	6	3.75e-07	2.3e-05	Isotype switching
Process	51	3.91e-07	2.38e-05	Organic substance biosynthetic process
Component	4	6.72e-07	2.41e-05	Rad51B-Rad51C-Rad51D-XRCC2 complex
Component	4	6.72e-07	2.41e-05	DNA replication factor A complex
Component	4	6.72e-07	2.41e-05	DNA-dependent protein kinase-DNA ligase 4 complex
Component	4	6.72e-07	2.41e-05	Zeta DNA polymerase complex
Component	4	6.72e-07	2.41e-05	RecQ family helicase-topoisomerase III complex
Component	4	6.72e-07	2.41e-05	BRCA1-B complex
Component	4	6.72e-07	2.41e-05	GINS complex
Function	10	3.45e-07	2.43e-05	Protein N-terminus binding
HPO	7	9.72e-07	2.47e-05	Basal cell carcinoma
HPO	7	9.72e-07	2.47e-05	Demyelinating peripheral neuropathy
KEGG	12	1.11e-06	2.48e-05	Epstein-Barr virus infection
COMPARTMENTS	14	8.3e-07	2.48e-05	Ubiquitin ligase complex
Keyword	4	1.2e-06	2.52e-05	DNA excision
HPO	10	1.04e-06	2.63e-05	Decreased testicular size
HPO	8	1.05e-06	2.65e-05	Aplasia/Hypoplasia of the breasts
WikiPathways	9	1.05e-06	2.66e-05	Small cell lung cancer
KEGG	8	1.28e-06	2.69e-05	Pancreatic cancer
COMPARTMENTS	28	9.14e-07	2.7e-05	Microtubule cytoskeleton
TISSUES	108	1.82e-07	2.76e-05	Urogenital system
COMPARTMENTS	9	9.71e-07	2.83e-05	Nuclear DNA-directed RNA polymerase complex
Process	152	4.76e-07	2.88e-05	Regulation of biological process
HPO	6	1.22e-06	3.06e-05	Adipose tissue loss
HPO	26	1.32e-06	3.29e-05	Mean corpuscular volume
Process	5	5.47e-07	3.3e-05	Somatic hypermutation of immunoglobulin genes
HPO	10	1.36e-06	3.4e-05	Neoplasm of the central nervous system
Process	6	5.71e-07	3.43e-05	RNA-templated DNA biosynthetic process
COMPARTMENTS	4	1.2e-06	3.45e-05	FANCM-MHF complex
COMPARTMENTS	4	1.2e-06	3.45e-05	Elg1 RFC-like complex
COMPARTMENTS	4	1.2e-06	3.45e-05	Checkpoint clamp complex
RCTM	4	1.98e-06	3.48e-05	Sensing of DNA Double Strand Breaks
HPO	11	1.46e-06	3.64e-05	Narrow palate
Function	5	5.47e-07	3.8e-05	Single-stranded telomeric DNA binding
HPO	32	1.54e-06	3.81e-05	Abnormal nasal morphology
Component	4	1.2e-06	3.84e-05	Checkpoint clamp complex
Component	4	1.2e-06	3.84e-05	DNA replication factor C complex
HPO	9	1.57e-06	3.88e-05	Sparse scalp hair
KEGG	19	2.02e-06	3.99e-05	Pathways in cancer
Process	4	6.72e-07	4.02e-05	Response to intra-S DNA damage checkpoint signaling
Process	4	6.72e-07	4.02e-05	Lagging strand elongation
Process	4	6.72e-07	4.02e-05	Leading strand elongation
RCTM	6	2.37e-06	4.12e-05	Oncogene Induced Senescence
HPO	6	1.71e-06	4.24e-05	Craniofacial hyperostosis
DISEASES	7	4.17e-07	4.36e-05	Autosomal recessive cerebellar ataxia
RCTM	34	2.56e-06	4.43e-05	Post-translational protein modification
HPO	7	1.82e-06	4.48e-05	Ectropion
HPO	13	1.87e-06	4.61e-05	Abnormality of neutrophils
HPO	17	1.93e-06	4.73e-05	Peripheral neuropathy
HPO	4	1.98e-06	4.86e-05	Slender nose
HPO	4	1.98e-06	4.86e-05	Increased cellular sensitivity to UV light
Process	6	8.45e-07	4.98e-05	Regulation of DNA damage checkpoint
Function	5	7.52e-07	5.15e-05	DNA N-glycosylase activity
HPO	10	2.14e-06	5.21e-05	Bifid uvula
RCTM	4	3.09e-06	5.31e-05	2-LTR circle formation
COMPARTMENTS	4	1.98e-06	5.39e-05	DNA replication factor C complex
RCTM	8	3.19e-06	5.43e-05	Senescence-Associated Secretory Phenotype (SASP)
Process	89	9.53e-07	5.58e-05	Positive regulation of cellular process
COMPARTMENTS	12	2.11e-06	5.65e-05	Condensed chromosome
Function	39	8.5e-07	5.67e-05	Double-stranded DNA binding
Process	24	9.79e-07	5.71e-05	Immune system development
Process	5	1.01e-06	5.88e-05	Inner cell mass cell proliferation
Component	4	1.98e-06	6.15e-05	FANCM-MHF complex
HPO	8	2.68e-06	6.52e-05	Conjunctivitis
Function	5	1.01e-06	6.65e-05	Mismatched DNA binding
DISEASES	4	6.72e-07	6.86e-05	Xeroderma pigmentosum group F
DISEASES	4	6.72e-07	6.86e-05	Xeroderma pigmentosum group C
HPO	5	2.83e-06	6.87e-05	Squamous cell carcinoma of the skin
HPO	5	2.83e-06	6.87e-05	Cutaneous melanoma
Process	4	1.2e-06	6.94e-05	Nucleotide-excision repair, DNA gap filling
HPO	7	2.87e-06	6.94e-05	Neuroepithelial neoplasm
HPO	4	3.09e-06	7.43e-05	Anemic pallor
Function	4	1.2e-06	7.49e-05	Crossover junction endodeoxyribonuclease activity
Function	4	1.2e-06	7.49e-05	MutSalpha complex binding
Function	4	1.2e-06	7.49e-05	Y-form DNA binding
WikiPathways	4	3.09e-06	7.55e-05	DDX1 as a regulatory component of the Drosha microprocessor
Function	7	1.26e-06	7.57e-05	Cyclin-dependent protein serine/threonine kinase regulator activity
Process	5	1.34e-06	7.71e-05	DNA damage response, signal transduction resulting in transcription
Process	5	1.34e-06	7.71e-05	Response to UV-C
HPO	27	3.3e-06	7.89e-05	Increased inflammatory response
Process	8	1.41e-06	8.09e-05	Positive regulation of DNA recombination
RCTM	6	4.91e-06	8.27e-05	DNA Damage Recognition in GG-NER
RCTM	10	4.89e-06	8.27e-05	HIV Life Cycle
HPO	6	3.71e-06	8.83e-05	Pterygium
HPO	24	4.13e-06	9.78e-05	Abnormal external nose morphology
Component	33	3.23e-06	9.86e-05	Microtubule cytoskeleton
Process	31	1.75e-06	9.97e-05	Regulation of organelle organization
WikiPathways	9	4.28e-06	0.0001	CKAP4 signaling pathway map
HPO	5	4.4e-06	0.0001	Progeroid facial appearance
RCTM	4	6.6e-06	0.00011	Displacement of DNA glycosylase by APEX1
HPO	7	4.87e-06	0.00011	Neoplasm of the stomach
NetworkNeighborAL	4	1.2e-06	0.00011	VCB complex, and VHL beta domain
NetworkNeighborAL	4	1.2e-06	0.00011	Error-prone translesion synthesis
Process	4	1.98e-06	0.00011	Mitochondrial DNA repair
WikiPathways	4	4.6e-06	0.00011	NIPBL role in DNA damage - Cornelia de Lange syndrome
WikiPathways	4	4.6e-06	0.00011	Hijack of ubiquitination by SARS-CoV-2
NetworkNeighborAL	4	1.2e-06	0.00011	Cyclin E1-CDK2 complex, and Omphalocele
Process	8	1.87e-06	0.00011	Negative regulation of G1/S transition of mitotic cell cycle
SMART	4	6.72e-07	0.00011	DNA polymerase type-B family
DISEASES	4	1.2e-06	0.00012	Werner syndrome
HPO	12	5.25e-06	0.00012	Abnormality of the pancreas
DISEASES	4	1.2e-06	0.00012	Nijmegen breakage syndrome
WikiPathways	6	5.62e-06	0.00012	Bladder cancer
DISEASES	4	1.2e-06	0.00012	Rothmund-Thomson syndrome
HPO	22	5.15e-06	0.00012	Mean corpuscular hemoglobin
KEGG	6	6.41e-06	0.00012	Bladder cancer
HPO	7	5.38e-06	0.00013	Embryonal neoplasm
WikiPathways	7	5.94e-06	0.00013	Prader-Willi and Angelman syndrome
Process	17	2.32e-06	0.00013	Response to xenobiotic stimulus
Process	26	2.26e-06	0.00013	Protein modification by small protein conjugation or removal
RCTM	5	7.94e-06	0.00013	Telomere Extension By Telomerase
KEGG	10	7.97e-06	0.00014	Hepatitis B
KEGG	10	8.4e-06	0.00014	MicroRNAs in cancer
Process	7	2.57e-06	0.00014	Positive regulation of fibroblast proliferation
Keyword	8	7.64e-06	0.00015	Meiosis
Keyword	6	7.29e-06	0.00015	Telomere
HPO	5	6.58e-06	0.00015	Colorectal polyposis
HPO	11	6.56e-06	0.00015	Abnormal nasal dorsum morphology
HPO	4	6.6e-06	0.00015	Ivory epiphyses
HPO	4	6.6e-06	0.00015	Numerous pigmented freckles
SMART	4	1.2e-06	0.00016	ERCC4 domain
SMART	4	1.2e-06	0.00016	Xeroderma pigmentosum G N-region
Process	7	2.87e-06	0.00016	Regulation of telomere maintenance via telomerase
SMART	4	1.2e-06	0.00016	Helix-hairpin-helix class 2 (Pol1 family) motifs
SMART	4	1.98e-06	0.00016	Helix-hairpin-helix DNA-binding motif class 1
Function	6	2.76e-06	0.00016	Cyclin binding
NetworkNeighborAL	4	1.98e-06	0.00016	NIPBL role in DNA damage - Cornelia de Lange syndrome
SMART	4	1.2e-06	0.00016	Xeroderma pigmentosum G I-region
KEGG	7	1.04e-05	0.00017	Non-small cell lung cancer
COMPARTMENTS	9	6.34e-06	0.00017	ATPase complex
Process	4	3.09e-06	0.00017	DNA double-strand break processing involved in repair via single-strand annealing
HPO	7	7.2e-06	0.00017	Abnormality of the auditory canal
Process	4	3.09e-06	0.00017	DNA replication, synthesis of RNA primer
HPO	11	7.2e-06	0.00017	Alopecia
Process	4	3.09e-06	0.00017	Replication-born double-strand break repair via sister chromatid exchange
Process	4	3.09e-06	0.00017	Regulation of mitotic recombination
Function	5	2.83e-06	0.00017	5-3 exonuclease activity
RCTM	5	1.13e-05	0.00018	Cyclin A/B1/B2 associated events during G2/M transition
Process	9	3.49e-06	0.00019	Regulation of cyclin-dependent protein serine/threonine kinase activity
HPO	10	8.4e-06	0.00019	Camptodactyly of finger
Process	36	3.59e-06	0.00019	Regulation of protein modification process
Component	199	6.48e-06	0.0002	Cellular anatomical entity
Component	9	6.75e-06	0.0002	Nuclear DNA-directed RNA polymerase complex
HPO	21	8.81e-06	0.0002	Abnormal hair quantity
HPO	9	8.64e-06	0.0002	Abnormality of female external genitalia
KEGG	7	1.35e-05	0.00021	Glioma
Process	7	3.97e-06	0.00021	G2/M transition of mitotic cell cycle
HPO	4	9.16e-06	0.00021	Abnormality of amino acid metabolism
HPO	12	9.03e-06	0.00021	Fever
InterPro	10	5.07e-07	0.00021	Helicase superfamily 1/2, ATP-binding domain
KEGG	7	1.47e-05	0.00021	Melanoma
WikiPathways	7	1.04e-05	0.00021	Melanoma
Process	16	4.09e-06	0.00022	In utero embryonic development
Process	9	4.28e-06	0.00023	Blastocyst development
Component	7	7.91e-06	0.00023	Germ cell nucleus
Process	4	4.6e-06	0.00024	Pyrimidine dimer repair
RCTM	7	1.59e-05	0.00026	Diseases of programmed cell death
KEGG	7	1.88e-05	0.00026	Chronic myeloid leukemia
HPO	10	1.14e-05	0.00026	Abnormality of the ovary
Function	4	4.6e-06	0.00026	Single-stranded DNA helicase activity
Function	4	4.6e-06	0.00026	5-3 DNA helicase activity
InterPro	4	6.72e-07	0.00027	DNA-directed DNA polymerase, family B, exonuclease domain
InterPro	4	6.72e-07	0.00027	DNA-directed DNA polymerase, family B, multifunctional domain
InterPro	4	6.72e-07	0.00027	DNA polymerase, palm domain superfamily
HPO	17	1.19e-05	0.00027	Dysarthria
InterPro	4	6.72e-07	0.00027	GINS, helical bundle-like domain superfamily
InterPro	4	6.72e-07	0.00027	DNA-directed DNA polymerase, family B
HPO	8	1.26e-05	0.00028	Erythema
Process	36	5.23e-06	0.00028	Positive regulation of molecular function
HPO	7	1.24e-05	0.00028	Arteriosclerosis
WikiPathways	7	1.47e-05	0.00029	Non-small cell lung cancer
WikiPathways	7	1.47e-05	0.00029	Head and neck squamous cell carcinoma
RCTM	3	1.96e-05	0.00031	Evasion of Oxidative Stress Induced Senescence Due to Defective p16INK4A binding to CDK4 and CDK6
Keyword	4	1.64e-05	0.00031	Progressive external ophthalmoplegia
RCTM	3	1.96e-05	0.00031	Evasion of Oncogene Induced Senescence Due to Defective p16INK4A binding to CDK4 and CDK6
Keyword	4	1.64e-05	0.00031	DNA synthesis
Process	11	5.97e-06	0.00031	B cell activation
HPO	10	1.39e-05	0.00031	Decreased circulating antibody level
RCTM	3	1.96e-05	0.00031	Phosphorylation of proteins involved in the G2/M transition by Cyclin A:Cdc2 complexes
Process	8	6.09e-06	0.00032	Regulation of fibroblast proliferation
Process	12	6.22e-06	0.00032	protein-DNA complex assembly
RCTM	4	2.13e-05	0.00033	IRF3-mediated induction of type I IFN
Process	5	6.58e-06	0.00034	Telomere maintenance via telomerase
WikiPathways	6	1.84e-05	0.00035	TROP2 regulatory signaling
WikiPathways	5	1.84e-05	0.00035	Sphingolipid metabolism in senescence
HPO	5	1.58e-05	0.00035	Stomach cancer
Keyword	3	1.96e-05	0.00036	Li-Fraumeni syndrome
HPO	11	1.6e-05	0.00036	Abnormal immunoglobulin level
InterPro	4	1.2e-06	0.00037	Helix-hairpin-helix motif, class 2
Process	6	7.29e-06	0.00037	Negative regulation of DNA biosynthetic process
Process	14	7.14e-06	0.00037	Apoptotic signaling pathway
HPO	18	1.67e-05	0.00037	Mean corpuscular hemoglobin concentration
InterPro	4	1.2e-06	0.00037	XPG/Rad2 endonuclease
HPO	6	1.65e-05	0.00037	Short chin
WikiPathways	6	2.04e-05	0.00037	Photodynamic therapy-induced AP-1 survival signaling
InterPro	4	1.2e-06	0.00037	Restriction endonuclease type II-like
InterPro	4	1.2e-06	0.00037	ERCC4 domain
InterPro	4	1.2e-06	0.00037	XPG-I domain
InterPro	4	1.2e-06	0.00037	DNA polymerase lambda lyase domain superfamily
InterPro	4	1.2e-06	0.00037	5-3 exonuclease, C-terminal domain superfamily
InterPro	4	1.2e-06	0.00037	DNA polymerase family B, thumb domain
InterPro	4	1.2e-06	0.00037	DNA helicase, ATP-dependent, RecQ type
Process	93	7.47e-06	0.00038	Positive regulation of biological process
HPO	11	1.81e-05	0.0004	Specific learning disability
Process	8	8.23e-06	0.00042	Signal transduction by p53 class mediator
HPO	8	1.88e-05	0.00042	Narrow face
HPO	3	1.96e-05	0.00043	Retinoblastoma
HPO	20	1.98e-05	0.00044	Flexion contracture
HPO	20	1.98e-05	0.00044	Joint contracture
InterPro	4	1.98e-06	0.00045	DNA polymerase III, clamp loader complex, gamma/delta/delta subunit, C-terminal
DISEASES	6	4.91e-06	0.00045	Urinary bladder cancer
InterPro	4	1.98e-06	0.00045	XPG, N-terminal
Process	4	9.16e-06	0.00047	Transcription-coupled nucleotide-excision repair
HPO	4	2.13e-05	0.00047	Birth length less than 3rd percentile
HPO	4	2.13e-05	0.00047	Complete duplication of thumb phalanx
HPO	5	2.14e-05	0.00047	Non-Hodgkin lymphoma
HPO	7	2.2e-05	0.00048	Retinopathy
HPO	11	2.22e-05	0.00049	Photophobia
RCTM	11	3.28e-05	0.0005	HIV Infection
COMPARTMENTS	3	1.96e-05	0.00051	MCM core complex
Function	4	9.16e-06	0.00051	G-quadruplex DNA binding
COMPARTMENTS	3	1.96e-05	0.00051	Cyclin E1-CDK2 complex
COMPARTMENTS	3	1.96e-05	0.00051	Nucleotide-excision repair factor 1 complex
HPO	22	2.33e-05	0.00051	Abnormal cerebellum morphology
Function	4	9.16e-06	0.00051	Four-way junction DNA binding
KEGG	13	3.87e-05	0.00052	Human papillomavirus infection
KEGG	9	3.93e-05	0.00052	Cushing syndrome
Process	9	1.03e-05	0.00052	Regulation of chromosome segregation
Process	6	1.05e-05	0.00053	DNA damage response, signal transduction by p53 class mediator
HPO	8	2.42e-05	0.00053	Nevus
HPO	5	2.48e-05	0.00054	Reticulocytopenia
HPO	5	2.48e-05	0.00054	Osteosarcoma
COMPARTMENTS	4	2.13e-05	0.00054	Nuclear telomere cap complex
COMPARTMENTS	4	2.13e-05	0.00054	Lateral element
Component	3	1.96e-05	0.00055	ERCC4-ERCC1 complex
Component	3	1.96e-05	0.00055	Nucleotide-excision repair factor 1 complex
Component	4	2.13e-05	0.00055	Nuclear telomere cap complex
Component	6	2.04e-05	0.00055	Male germ cell nucleus
Component	3	1.96e-05	0.00055	Replication fork protection complex
Component	3	1.96e-05	0.00055	Elg1 RFC-like complex
Component	3	1.96e-05	0.00055	DNA ligase IV complex
Component	3	1.96e-05	0.00055	Cyclin E1-CDK2 complex
Component	3	1.96e-05	0.00055	XPC complex
HPO	8	2.57e-05	0.00056	Abnormal rectum morphology
TISSUES	29	4.2e-06	0.00057	Uterus
HPO	4	2.71e-05	0.00058	Complete duplication of phalanx of hand
Component	13	2.34e-05	0.00058	Ubiquitin ligase complex
HPO	15	2.68e-05	0.00058	Mean reticulocyte volume
HPO	7	2.76e-05	0.00059	Thin skin
InterPro	9	2.83e-06	0.0006	Helicase, C-terminal
HPO	5	2.85e-05	0.00061	Aplastic anemia
HPO	5	2.85e-05	0.00061	Acute lymphoblastic leukemia
HPO	11	2.92e-05	0.00062	Corneal opacity
TISSUES	5	5.4e-06	0.00062	Skin fibroblast cell line
WikiPathways	5	3.74e-05	0.00066	Type 2 papillary renal cell carcinoma
Component	4	2.71e-05	0.00066	Lateral element
Function	19	1.23e-05	0.00067	Transcription factor binding
HPO	13	3.21e-05	0.00068	Aplasia/hypoplasia involving bones of the lower limbs
HPO	9	3.23e-05	0.00068	Abnormal lymphocyte morphology
HPO	8	3.28e-05	0.00069	Age at menopause
Process	29	1.38e-05	0.0007	Positive regulation of catalytic activity
HPO	4	3.41e-05	0.00071	Hypoplastic pelvis
HPO	3	3.4e-05	0.00071	Abnormal tibial metaphysis morphology
HPO	3	3.4e-05	0.00071	Patchy demyelination of subcortical white matter
RCTM	10	4.83e-05	0.00073	Mitotic G2-G2/M phases
RCTM	11	5.3e-05	0.00079	Neddylation
Process	55	1.59e-05	0.0008	Regulation of molecular function
Component	3	3.4e-05	0.00081	DNA-dependent protein kinase complex
Component	3	3.4e-05	0.00081	Delta DNA polymerase complex
Component	3	3.4e-05	0.00081	Mre11 complex
Process	4	1.64e-05	0.00082	Cellular response to X-ray
HPO	10	3.93e-05	0.00082	Immunodeficiency
Process	4	1.64e-05	0.00082	Base-excision repair, AP site formation
COMPARTMENTS	3	3.4e-05	0.00082	Delta DNA polymerase complex
COMPARTMENTS	3	3.4e-05	0.00082	Cyclin D1-CDK4 complex
COMPARTMENTS	3	3.4e-05	0.00082	MCM8-MCM9 complex
HPO	12	4.06e-05	0.00084	Joint hypermobility
HPO	12	4.06e-05	0.00084	Abnormality of the vasculature of the eye
HPO	5	4.25e-05	0.00088	Premature graying of hair
HPO	6	4.42e-05	0.00091	Malignant neoplasm of the central nervous system
Function	13	1.73e-05	0.00093	Ubiquitin protein ligase binding
HPO	34	4.56e-05	0.00094	Erythrocyte indices
Process	8	1.88e-05	0.00094	Regulation of signal transduction by p53 class mediator
Process	8	1.88e-05	0.00094	Regulation of sister chromatid segregation
Process	3	1.96e-05	0.00097	Telomeric DNA-containing double minutes formation
Process	3	1.96e-05	0.00097	Negative regulation of protection from non-homologous end joining at telomere
Process	3	1.96e-05	0.00097	DNA replication preinitiation complex assembly
Process	3	1.96e-05	0.00097	Regulation of single strand break repair
Process	9	2.03e-05	0.00099	Positive regulation of protein modification by small protein conjugation or removal
Process	4	2.13e-05	0.001	Regulation of nuclear cell cycle DNA replication
Function	3	1.96e-05	0.001	DNA ligase (ATP) activity
Function	44	2.03e-05	0.001	Transferase activity
Function	3	1.96e-05	0.001	DNA-dependent protein kinase activity
HPO	10	5.03e-05	0.001	Narrow mouth
HPO	6	4.82e-05	0.001	Decreased circulating IgG level
Process	4	2.13e-05	0.001	UV-damage excision repair
Function	3	1.96e-05	0.001	DNA clamp loader activity
RCTM	4	7.55e-05	0.0011	Transcription of E2F targets under negative control by DREAM complex
HPO	6	5.26e-05	0.0011	Melanocytic nevus
HPO	14	5.31e-05	0.0011	Abnormality of the voice
HPO	3	5.4e-05	0.0011	Widely spaced primary teeth
HPO	3	5.4e-05	0.0011	Hypoplasia of the primary teeth
HPO	6	5.26e-05	0.0011	Simplified gyral pattern
Process	7	2.2e-05	0.0011	Protein autoubiquitination
Function	4	2.13e-05	0.0011	DNA-(apurinic or apyrimidinic site) endonuclease activity
Function	4	2.13e-05	0.0011	3-5-exodeoxyribonuclease activity
KEGG	7	8.7e-05	0.0011	Prostate cancer
Process	17	2.4e-05	0.0012	Positive regulation of organelle organization
COMPARTMENTS	3	5.4e-05	0.0012	Cyclin A2-CDK2 complex
COMPARTMENTS	4	5.18e-05	0.0012	Enzyme activator complex
Process	20	2.54e-05	0.0012	Embryo development ending in birth or egg hatching
Component	3	5.4e-05	0.0012	Cyclin A2-CDK2 complex
HPO	13	6.03e-05	0.0012	Limb joint contracture
RCTM	3	8.04e-05	0.0012	PTK6 Regulates Cell Cycle
KEGG	8	9.62e-05	0.0012	Ubiquitin mediated proteolysis
Process	4	2.71e-05	0.0013	Positive regulation of DNA-templated DNA replication
WikiPathways	4	7.55e-05	0.0013	TP53 network
Process	4	2.71e-05	0.0013	Telomere maintenance in response to DNA damage
Process	45	2.71e-05	0.0013	Regulation of catalytic activity
HPO	4	6.29e-05	0.0013	Adenomatous colonic polyposis
Process	4	2.71e-05	0.0013	DNA damage response, signal transduction by p53 class mediator resulting in transcription of p21 class mediator
WikiPathways	6	8.61e-05	0.0014	Thyroid stimulating hormone (TSH) signaling pathway
WikiPathways	6	7.96e-05	0.0014	Pathways affected in adenoid cystic carcinoma
HPO	14	7.11e-05	0.0014	Thickened skin
HPO	6	6.77e-05	0.0014	Intellectual disability, progressive
InterPro	4	6.6e-06	0.0014	RuvA domain 2-like
InterPro	7	7.2e-06	0.0014	Ribonuclease H-like superfamily
HPO	11	6.77e-05	0.0014	Abnormality of the elbow
WikiPathways	10	9.34e-05	0.0015	Ciliary landscape
SMART	3	1.96e-05	0.0015	Minichromosome  maintenance proteins
Process	5	3.27e-05	0.0015	Intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediator
HPO	8	7.48e-05	0.0015	Carious teeth
Keyword	4	8.99e-05	0.0016	SCID
Function	3	3.4e-05	0.0016	Telomeric D-loop binding
Function	3	3.4e-05	0.0016	MutLalpha complex binding
Process	3	3.4e-05	0.0016	Nucleotide-excision repair, DNA incision, 5-to lesion
HPO	3	8.04e-05	0.0016	Peripheral dysmyelination
HPO	3	8.04e-05	0.0016	Brain neoplasm
HPO	6	7.96e-05	0.0016	Abnormal T cell count
HPO	13	8.23e-05	0.0016	Abnormality of temperature regulation
HPO	3	8.04e-05	0.0016	Square pelvis bone
HPO	3	8.04e-05	0.0016	Normal pressure hydrocephalus
RCTM	5	0.00011	0.0016	Defective pyroptosis
Process	3	3.4e-05	0.0016	DNA recombinase assembly
Process	3	3.4e-05	0.0016	Telomeric 3 overhang formation
Process	3	3.4e-05	0.0016	Cellular response to camptothecin
Process	3	3.4e-05	0.0016	Positive regulation of t-circle formation
Function	3	3.4e-05	0.0016	Double-stranded DNA exodeoxyribonuclease activity
Process	6	3.68e-05	0.0017	Intrinsic apoptotic signaling pathway by p53 class mediator
HPO	6	8.61e-05	0.0017	Neoplasm of the colon
HPO	11	8.3e-05	0.0017	Camptodactyly
RCTM	37	0.00012	0.0017	Metabolism of proteins
HPO	8	8.71e-05	0.0017	Abnormal lymphocyte count
Process	5	3.74e-05	0.0017	Histone phosphorylation
DISEASES	3	1.96e-05	0.0018	DNA ligase IV deficiency
DISEASES	3	1.96e-05	0.0018	Fanconi anemia complementation group D1
DISEASES	3	1.96e-05	0.0018	Xeroderma pigmentosum group D
DISEASES	3	1.96e-05	0.0018	Xeroderma pigmentosum group A
DISEASES	3	1.96e-05	0.0018	Severe combined immunodeficiency with sensitivity to ionizing radiation
HPO	4	8.99e-05	0.0018	Duplicated collecting system
Pfam	4	6.72e-07	0.0018	MCM N-terminal domain
RCTM	6	0.00013	0.0019	CDK-mediated phosphorylation and removal of Cdc6
DISEASES	8	2.27e-05	0.0019	Cerebellar ataxia
RCTM	5	0.00013	0.0019	Base-Excision Repair, AP Site Formation
HPO	9	9.67e-05	0.0019	Abnormal dental enamel morphology
Keyword	9	0.00011	0.002	Tumor suppressor
HPO	11	0.0001	0.002	Upper-limb joint contracture
HPO	6	0.0001	0.002	Gastrointestinal atresia
HPO	12	0.0001	0.002	Diarrhea
HPO	16	9.99e-05	0.002	Reduced tendon reflexes
HPO	7	0.0001	0.002	Hypoplasia of teeth
TISSUES	160	1.92e-05	0.002	Whole body
TISSUES	13	1.79e-05	0.002	Uterine cervix
KEGG	8	0.00017	0.002	Breast cancer
HPO	5	0.00011	0.0021	Decreased circulating IgA level
HPO	5	0.00011	0.0021	Abnormality of the thymus
HPO	3	0.00011	0.0022	Ivory epiphyses of the phalanges of the hand
Process	8	4.88e-05	0.0022	Positive regulation of protein ubiquitination
Process	7	4.88e-05	0.0022	Multicellular organism growth
Process	4	5.18e-05	0.0023	Protein localization to chromosome, telomeric region
HPO	26	0.00012	0.0023	Abnormal fundus morphology
HPO	21	0.00012	0.0023	Abnormality of the dentition
Process	7	5.22e-05	0.0023	Positive regulation of double-strand break repair
Process	20	5.14e-05	0.0023	Cell population proliferation
Process	19	5.17e-05	0.0023	Chordate embryonic development
Process	3	5.4e-05	0.0024	Positive regulation of DNA ligation
Process	3	5.4e-05	0.0024	Double-strand break repair via alternative nonhomologous end joining
COMPARTMENTS	4	0.00011	0.0024	Cul2-RING ubiquitin ligase complex
Process	3	5.4e-05	0.0024	Strand invasion
Process	3	5.4e-05	0.0024	Error-free translesion synthesis
Function	3	5.4e-05	0.0025	ATP-dependent DNA/DNA annealing activity
Function	3	5.4e-05	0.0025	5-deoxyribose-5-phosphate lyase activity
HPO	7	0.00013	0.0025	Hypoplasia of the maxilla
Process	8	5.75e-05	0.0025	Regulation of DNA binding
WikiPathways	3	0.00016	0.0025	Dual hijack model of Vif in HIV infection
RCTM	11	0.00018	0.0026	Deubiquitination
Process	7	5.96e-05	0.0026	Regulation of mitotic metaphase/anaphase transition
SMART	5	3.74e-05	0.0026	Domain present in cyclins, TFIIB and Retinoblastoma
COMPARTMENTS	3	0.00011	0.0026	Elongin complex
DISEASES	3	3.4e-05	0.0027	Spinocerebellar ataxia type 1 with axonal neuropathy
DISEASES	4	3.41e-05	0.0027	Lynch syndrome
HPO	22	0.00014	0.0027	Abnormal lung morphology
DISEASES	3	3.4e-05	0.0027	Baller-Gerold syndrome
Process	5	6.13e-05	0.0027	Cellular response to alkaloid
DISEASES	3	3.4e-05	0.0027	Rapadilino syndrome
HPO	10	0.00015	0.0028	Abnormality of extrapyramidal motor function
HPO	18	0.00014	0.0028	Low-set ears
HPO	11	0.00015	0.0028	Tooth agenesis
HPO	11	0.00015	0.0028	Abnormal female reproductive system physiology
HPO	8	0.00015	0.0028	Blepharophimosis
Process	6	6.77e-05	0.003	Homologous chromosome segregation
HPO	12	0.00016	0.0031	Short neck
RCTM	9	0.00023	0.0032	G2/M Transition
Process	5	7.7e-05	0.0034	Regulation of DNA damage response, signal transduction by p53 class mediator
HPO	7	0.00018	0.0035	Urinary tract neoplasm
COMPARTMENTS	3	0.00016	0.0035	Cul5-RING ubiquitin ligase complex
COMPARTMENTS	3	0.00016	0.0035	Primosome complex
Component	3	0.00016	0.0035	Cul5-RING ubiquitin ligase complex
Process	3	8.04e-05	0.0035	Double-strand break repair via classical nonhomologous end joining
Function	3	8.04e-05	0.0036	RNA-DNA hybrid ribonuclease activity
InterPro	3	1.96e-05	0.0036	DNA polymerase alpha/delta/epsilon, subunit B
InterPro	6	2.51e-05	0.0036	SMAD/FHA domain superfamily
InterPro	3	1.96e-05	0.0036	DNA ligase, ATP-dependent, N-terminal
InterPro	6	1.84e-05	0.0036	ATPase, AAA-type, core
Process	28	8.41e-05	0.0036	Regulation of phosphorylation
InterPro	3	1.96e-05	0.0036	DNA ligase, ATP-dependent, C-terminal
InterPro	3	1.96e-05	0.0036	DNA ligase, ATP-dependent, central
InterPro	3	1.96e-05	0.0036	DNA ligase, ATP-dependent, conserved site
InterPro	3	1.96e-05	0.0036	DNA-directed DNA polymerase, family B, conserved site
InterPro	3	1.96e-05	0.0036	GINS subunit, domain A
InterPro	6	1.84e-05	0.0036	Ribonuclease H superfamily
InterPro	3	1.96e-05	0.0036	DNA ligase, ATP-dependent, N-terminal domain superfamily
InterPro	3	1.96e-05	0.0036	Replication factor A protein-like
InterPro	3	1.96e-05	0.0036	PNK, FHA domain
InterPro	3	1.96e-05	0.0036	DNA ligase, ATP-dependent
HPO	9	0.00019	0.0036	Abnormal adipose tissue morphology
Process	10	8.67e-05	0.0037	Regulation of protein ubiquitination
HPO	11	0.00019	0.0037	Flexion contracture of digit
WikiPathways	7	0.00024	0.0037	Spinal cord injury
HPO	10	0.00019	0.0037	Abnormal large intestine morphology
HPO	8	0.0002	0.0038	Aplasia/Hypoplasia involving bones of the thorax
Process	4	8.99e-05	0.0038	DNA damage response, signal transduction by p53 class mediator resulting in cell cycle arrest
Process	4	8.99e-05	0.0038	Hematopoietic stem cell differentiation
Component	4	0.00017	0.0038	Cul2-RING ubiquitin ligase complex
InterPro	4	2.71e-05	0.0038	PIN-like domain superfamily
HPO	3	0.00021	0.0039	Loss of facial adipose tissue
HPO	21	0.0002	0.0039	Ataxia
DISEASES	3	5.4e-05	0.0039	Serous cystadenocarcinoma
Process	10	9.34e-05	0.004	Peptidyl-serine modification
HPO	6	0.00022	0.0041	Increased bone mineral density
HPO	31	0.00022	0.0041	Abnormal skeletal muscle morphology
HPO	9	0.00022	0.0041	Abnormal odontoid tissue morphology
RCTM	5	0.00029	0.0041	Formation of TC-NER Pre-Incision Complex
DISEASES	9	5.72e-05	0.0041	Gastrointestinal system cancer
HPO	4	0.00022	0.0041	Progressive external ophthalmoplegia
COMPARTMENTS	8	0.00019	0.0042	cullin-RING ubiquitin ligase complex
HPO	5	0.00023	0.0042	Duplication of thumb phalanx
HPO	7	0.00022	0.0042	Lymphopenia
Process	50	0.0001	0.0043	Macromolecule modification
NetworkNeighborAL	3	5.4e-05	0.0043	Cyclin-dependent kinase, regulatory subunit, and Phosphorylation of proteins involved in the G2/M transition by Cyclin A:Cdc2 complexes
NetworkNeighborAL	3	5.4e-05	0.0043	G2 Phase, and Familial retinoblastoma
NetworkNeighborAL	3	5.4e-05	0.0043	DNA recombinase mediator complex
NetworkNeighborAL	3	5.4e-05	0.0043	DNA replication factor A complex, and DNA primase activity
Process	19	0.0001	0.0044	Negative regulation of cellular component organization
Process	5	0.00011	0.0045	Sister chromatid cohesion
Process	14	0.00011	0.0046	Developmental growth
HPO	18	0.00025	0.0046	Abnormal location of ears
HPO	6	0.00025	0.0046	Enamel hypoplasia
InterPro	3	3.4e-05	0.0047	XPG conserved site
InterPro	3	3.4e-05	0.0047	ATP-dependent DNA helicase RecQ, zinc-binding domain
InterPro	3	3.4e-05	0.0047	DNA polymerase, thumb domain superfamily
InterPro	3	3.4e-05	0.0047	DNA polymerase family X, binding site
InterPro	3	3.4e-05	0.0047	DNA polymerase lambda, fingers domain
InterPro	3	3.4e-05	0.0047	DNA polymerase beta-like, N-terminal domain
InterPro	3	3.4e-05	0.0047	DNA-directed DNA polymerase X
HPO	4	0.00025	0.0047	Uveitis
InterPro	3	3.4e-05	0.0047	DNA polymerase family X
InterPro	3	3.4e-05	0.0047	DNA polymerase beta, thumb domain
InterPro	3	3.4e-05	0.0047	DNA polymerase beta, palm domain
Process	3	0.00011	0.0048	G-quadruplex DNA unwinding
InterPro	5	4.25e-05	0.0049	Cyclin-like domain
RCTM	6	0.00035	0.0049	APC/C-mediated degradation of cell cycle proteins
HPO	42	0.00028	0.0051	Abnormality of the musculature
HPO	7	0.00027	0.0051	Abnormality of the maxilla
Function	3	0.00011	0.0051	Double-stranded telomeric DNA binding
SMART	3	8.04e-05	0.0051	The FATC domain is named after FRAP, ATM, TRRAP C-terminal (PMID:10782091). The solution structure of the FATC domain suggests it plays a role in redox-dependent structural and cellular stability (PMID:15772072).
HPO	11	0.00029	0.0053	Abnormal number of teeth
HPO	4	0.00029	0.0053	Esophageal atresia
TISSUES	3	5.4e-05	0.0055	M cell
TISSUES	11	5.69e-05	0.0055	Erythroleukemia cell
HPO	22	0.0003	0.0056	Abnormality of coordination
KEGG	6	0.00052	0.0058	Endocrine resistance
HPO	12	0.00031	0.0058	Dyspnea
RCTM	3	0.00042	0.0058	HSF1 activation
KEGG	6	0.00055	0.0059	Progesterone-mediated oocyte maturation
InterPro	4	5.18e-05	0.0059	Cyclin, C-terminal domain
DISEASES	5	8.6e-05	0.006	Cholangiocarcinoma
Process	4	0.00014	0.006	Histone H2A monoubiquitination
Process	4	0.00014	0.006	Regulation of chromatin binding
HPO	3	0.00034	0.0061	Delayed eruption of primary teeth
HPO	6	0.00033	0.0061	Renal hypoplasia
Keyword	4	0.00036	0.0061	Cyclin
InterPro	3	5.4e-05	0.0061	PIK-related kinase, FAT
HPO	11	0.00034	0.0062	Abnormality of the scalp hair
WikiPathways	4	0.00041	0.0062	Tumor suppressor activity of SMARCB1
WikiPathways	6	0.00042	0.0063	Androgen receptor signaling pathway
RCTM	5	0.00046	0.0063	Transcriptional regulation of granulopoiesis
HPO	6	0.00035	0.0064	Horseshoe kidney
Process	3	0.00016	0.0064	DNA damage induced protein phosphorylation
RCTM	6	0.00047	0.0064	Oxidative Stress Induced Senescence
HPO	4	0.00036	0.0066	Glioma
HPO	4	0.00036	0.0066	Reduced subcutaneous adipose tissue
Process	8	0.00016	0.0067	Regulation of nuclear division
Function	3	0.00016	0.0068	5-3 exodeoxyribonuclease activity
RCTM	3	0.00051	0.0069	Cytosolic iron-sulfur cluster assembly
RCTM	3	0.00051	0.0069	Chk1/Chk2(Cds1) mediated inactivation of Cyclin B:Cdk1 complex
DISEASES	4	0.00011	0.0071	Chronic progressive external ophthalmoplegia
Function	15	0.00017	0.0072	DNA-binding transcription factor binding
HPO	5	0.0004	0.0072	Nevus count
HPO	8	0.0004	0.0072	Renal agenesis
HPO	10	0.0004	0.0072	Fatigue
Component	15	0.00033	0.0073	Transcription regulator complex
HPO	4	0.00041	0.0073	B lymphocytopenia
KEGG	5	0.0007	0.0073	Renal cell carcinoma
WikiPathways	4	0.0005	0.0074	Fluoropyrimidine activity
Process	24	0.00018	0.0075	Apoptotic process
Process	25	0.00018	0.0076	Regulation of protein phosphorylation
RCTM	2	0.0006	0.008	Defective DNA double strand break response due to BRCA1 loss of function
RCTM	2	0.0006	0.008	Defective DNA double strand break response due to BARD1 loss of function
RCTM	2	0.0006	0.008	Evasion of Oxidative Stress Induced Senescence Due to Defective p16INK4A binding to CDK4
RCTM	2	0.0006	0.008	Evasion of Oncogene Induced Senescence Due to Defective p16INK4A binding to CDK4
RCTM	2	0.0006	0.008	Abasic sugar-phosphate removal via the single-nucleotide replacement pathway
RCTM	5	0.00061	0.008	Cytosolic sensors of pathogen-associated DNA
HPO	10	0.00045	0.008	Abnormal rib morphology
HPO	13	0.00046	0.0082	Abnormality of upper limb joint
InterPro	4	7.55e-05	0.0083	Cyclin
TISSUES	49	8.99e-05	0.0084	Internal female genital organ
Process	3	0.00021	0.0084	Protein K6-linked ubiquitination
WikiPathways	2	0.0006	0.0086	Ultraconserved region 339 modulation of tumor suppressor microRNAs in cancer
Process	25	0.00021	0.0086	Cell death
WikiPathways	3	0.00061	0.0087	H19 action Rb-E2F1 signaling and CDK-Beta-catenin activity
InterPro	3	8.04e-05	0.0087	PIK-related kinase
InterPro	3	8.04e-05	0.0087	HRDC-like superfamily
InterPro	3	8.04e-05	0.0087	FATC domain
InterPro	3	8.04e-05	0.0087	Transcription factor CBF/NF-Y/archaeal histone domain
HPO	4	0.0005	0.009	Nephroblastoma
HPO	15	0.0005	0.009	Pain
HPO	3	0.00051	0.009	Pelvic kidney
Process	46	0.00023	0.0092	Protein modification process
KEGG	7	0.00092	0.0094	Gastric cancer
RCTM	4	0.00075	0.0097	Cleavage of the damaged purine
DISEASES	3	0.00016	0.0097	Trichothiodystrophy
RCTM	4	0.00075	0.0097	Recognition and association of DNA glycosylase with site containing an affected purine
DISEASES	5	0.00016	0.0097	Melanoma
Keyword	2	0.0006	0.0098	Primosome
InterPro	5	9.57e-05	0.0098	Cyclin-like superfamily
Process	31	0.00024	0.0098	Response to oxygen-containing compound
Process	29	0.00024	0.0098	Regulation of phosphate metabolic process
DISEASES	6	0.00017	0.01	Male reproductive organ cancer
HPO	5	0.00057	0.0101	Chronic diarrhea
HPO	6	0.00058	0.0102	Choreoathetosis
HPO	6	0.00058	0.0102	Decreased nerve conduction velocity
Process	6	0.00026	0.0105	Somite development
WikiPathways	4	0.00075	0.0105	Effect of progerin on genes involved in Hutchinson-Gilford progeria syndrome
Process	3	0.00027	0.0107	Mitochondrial DNA replication
Process	5	0.00027	0.0107	Homologous chromosome pairing at meiosis
Process	13	0.00027	0.0107	Histone modification
Process	3	0.00027	0.0107	Positive regulation of ligase activity
HPO	3	0.00061	0.0108	Absent earlobe
HPO	3	0.00061	0.0108	Absence of subcutaneous fat
HPO	7	0.00062	0.0108	Abnormal thyroid morphology
HPO	4	0.00062	0.0109	Long nose
Process	7	0.00027	0.0109	Regulation of mitotic nuclear division
RCTM	3	0.00086	0.011	Transcription of E2F targets under negative control by p107 (RBL1) and p130 (RBL2) in complex with HDAC1
HPO	6	0.00064	0.0112	Renal neoplasm
Component	3	0.00051	0.0112	Cul4A-RING E3 ubiquitin ligase complex
RCTM	5	0.0009	0.0114	Regulation of HSF1-mediated heat shock response
Function	3	0.00027	0.0115	TFIID-class transcription factor complex binding
NetworkNeighborAL	3	0.00016	0.0115	Drug-mediated inhibition of CDK4/CDK6 activity, and Regulation of cardiac muscle tissue regeneration
Function	3	0.00027	0.0115	G-rich strand telomeric DNA binding
Process	5	0.00029	0.0115	Male meiotic nuclear division
WikiPathways	3	0.00086	0.0118	ID signaling pathway
Process	36	0.0003	0.0119	Positive regulation of macromolecule biosynthetic process
HPO	15	0.00069	0.012	Respiratory tract infection
COMPARTMENTS	5	0.00057	0.0121	Nucleoid
HPO	11	0.0007	0.0122	Posteriorly rotated ears
HPO	9	0.0007	0.0123	Abnormality of the calf
HPO	8	0.00072	0.0125	Respiratory distress
COMPARTMENTS	2	0.0006	0.0126	Cyclin A1-CDK2 complex
COMPARTMENTS	2	0.0006	0.0126	Cyclin E2-CDK2 complex
COMPARTMENTS	2	0.0006	0.0126	PCNA-p21 complex
COMPARTMENTS	2	0.0006	0.0126	RecFOR complex
COMPARTMENTS	2	0.0006	0.0126	Ku70:Ku80 complex
COMPARTMENTS	2	0.0006	0.0126	DNA polymerase III complex
COMPARTMENTS	2	0.0006	0.0126	Gamma DNA polymerase complex
Process	16	0.00032	0.0126	Cellular response to organonitrogen compound
Component	2	0.0006	0.013	Gamma DNA polymerase complex
Component	2	0.0006	0.013	ATR-ATRIP complex
Component	2	0.0006	0.013	Rad51C-XRCC3 complex
Component	2	0.0006	0.013	Ku70:Ku80 complex
Component	2	0.0006	0.013	PCNA-p21 complex
Component	2	0.0006	0.013	Cyclin A1-CDK2 complex
Component	2	0.0006	0.013	Cyclin E2-CDK2 complex
Component	2	0.0006	0.013	Shu complex
Component	2	0.0006	0.013	MCM8-MCM9 complex
HPO	4	0.00075	0.013	Abnormal epiphysis morphology of the phalanges of the hand
HPO	6	0.00074	0.013	Abnormal nerve conduction velocity
Process	23	0.00033	0.013	Positive regulation of protein modification process
Component	8	0.0006	0.013	cullin-RING ubiquitin ligase complex
HPO	14	0.00076	0.0131	Abnormal myelination
Process	3	0.00034	0.0131	Cellular response to hydroxyurea
Process	5	0.00034	0.0132	Regulation of mitotic sister chromatid segregation
Process	17	0.00034	0.0133	Cellular response to nitrogen compound
KEGG	7	0.0014	0.0136	Hepatitis C
Function	4	0.00032	0.0137	Cyclin-dependent protein serine/threonine kinase activity
Function	12	0.00034	0.0141	RNA polymerase II-specific DNA-binding transcription factor binding
HPO	6	0.00082	0.0142	Skin rash
HPO	4	0.00082	0.0142	Basal ganglia calcification
HPO	4	0.00082	0.0142	Male hypogonadism
HPO	4	0.00082	0.0142	Abnormal astrocyte morphology
HPO	11	0.00082	0.0142	Abnormality of mouth size
Process	6	0.00037	0.0144	Centrosome cycle
COMPARTMENTS	3	0.00073	0.0145	Cul4A-RING E3 ubiquitin ligase complex
HPO	7	0.00085	0.0146	Sarcoma
RCTM	4	0.0012	0.0147	Cleavage of the damaged pyrimidine
RCTM	3	0.0012	0.0147	TP53 Regulates Transcription of Genes Involved in G2 Cell Cycle Arrest
RCTM	4	0.0012	0.0147	Recognition and association of DNA glycosylase with site containing an affected pyrimidine
HPO	3	0.00086	0.0148	Anodontia
HPO	28	0.00086	0.0148	Abdominal symptom
TISSUES	6	0.00017	0.0149	Fibroblast cell line
HPO	7	0.00088	0.0151	Abnormality of corneal size
KEGG	7	0.0016	0.0152	Hepatocellular carcinoma
RCTM	4	0.0013	0.0155	Formation of HIV-1 elongation complex containing HIV-1 Tat
DISEASES	5	0.00027	0.0155	Prostate cancer
HPO	9	0.00091	0.0156	Hyperkeratosis
RCTM	7	0.0013	0.0156	Factors involved in megakaryocyte development and platelet production
Process	3	0.00042	0.016	Regulation of helicase activity
HPO	6	0.00095	0.0161	Hypotelorism
RCTM	3	0.0013	0.0162	Regulation of TP53 Activity through Methylation
HPO	8	0.00096	0.0164	Gait ataxia
HPO	10	0.00097	0.0165	Abnormality of dental structure
Process	15	0.00043	0.0165	RNA biosynthetic process
Keyword	56	0.001	0.0166	Metal-binding
HPO	2	0.00099	0.0167	Subcortical white matter calcifications
HPO	2	0.00099	0.0167	Thymic hormone decreased
KEGG	6	0.0018	0.0169	Oocyte meiosis
HPO	3	0.001	0.017	Dry hair
HPO	11	0.001	0.0171	Cerebellar atrophy
Function	3	0.00042	0.0173	RNA polymerase II CTD heptapeptide repeat kinase activity
HPO	19	0.001	0.0176	Abnormal retinal morphology
RCTM	2	0.0015	0.0176	Transcriptional  activation of  cell cycle inhibitor p21
RCTM	4	0.0015	0.0176	Formation of HIV elongation complex in the absence of HIV Tat
COMPARTMENTS	5	0.0009	0.0176	Nuclear matrix
HPO	4	0.0011	0.018	Urticaria
HPO	4	0.0011	0.018	Gaze-evoked nystagmus
WikiPathways	5	0.0013	0.0181	Joubert syndrome
Process	7	0.00048	0.0182	Lymphocyte activation involved in immune response
DISEASES	4	0.00032	0.0183	Breast carcinoma
HPO	7	0.0011	0.0187	Abnormal bronchus morphology
Keyword	5	0.0012	0.0188	Multifunctional enzyme
Function	5	0.00046	0.0189	Basal RNA polymerase II transcription machinery binding
COMPARTMENTS	2	0.00099	0.0191	Beta-galactosidase complex
COMPARTMENTS	2	0.00099	0.0191	Rad51B-Rad51C complex
COMPARTMENTS	4	0.00098	0.0191	SCF ubiquitin ligase complex
Process	23	0.0005	0.0191	Embryo development
COMPARTMENTS	2	0.00099	0.0191	Pre-primosome complex
Component	2	0.00099	0.0193	Holliday junction resolvase complex
Component	2	0.00099	0.0193	Rb-E2F complex
Component	2	0.00099	0.0193	Slx1-Slx4 complex
Component	2	0.00099	0.0193	VCB complex
Function	97	0.00048	0.0195	Protein binding
WikiPathways	4	0.0015	0.0195	Aryl hydrocarbon receptor pathway
HPO	3	0.0012	0.0196	Severe combined immunodeficiency
HPO	3	0.0012	0.0196	Medulloblastoma
HPO	8	0.0012	0.0196	Ectopic calcification
RCTM	6	0.0017	0.0197	Transcriptional regulation by RUNX2
HPO	7	0.0012	0.0199	Abnormal nasopharynx morphology
HPO	66	0.0012	0.0204	Hematological measurement
HPO	11	0.0012	0.0206	Epidermal thickening
HPO	4	0.0013	0.0209	Abnormality of the radial head
HPO	4	0.0013	0.0209	Confusion
HPO	5	0.0013	0.0211	Postural instability
Process	23	0.00056	0.0211	Cellular response to oxygen-containing compound
Process	4	0.00056	0.0212	Positive regulation of telomere maintenance via telomerase
HPO	13	0.0013	0.0215	Recurrent respiratory infections
InterPro	10	0.00021	0.0217	Winged helix-like DNA-binding domain superfamily
HPO	3	0.0013	0.0221	Bronchomalacia
HPO	5	0.0013	0.0222	Sensorimotor neuropathy
Process	10	0.00059	0.0223	Cellular response to chemical stress
Process	2	0.0006	0.0224	Nucleotide-excision repair, DNA duplex unwinding
Process	2	0.0006	0.0224	Nucleotide-excision repair, DNA incision, 3-to lesion
Process	2	0.0006	0.0224	DNA replication, Okazaki fragment processing
Process	3	0.00061	0.0224	Positive regulation of chromatin binding
Process	2	0.0006	0.0224	Recombinational interstrand cross-link repair
Process	2	0.0006	0.0224	DNA replication proofreading
Process	2	0.0006	0.0224	Mismatch repair involved in maintenance of fidelity involved in DNA-dependent DNA replication
Process	2	0.0006	0.0224	Resolution of mitotic recombination intermediates
Process	2	0.0006	0.0224	Establishment of RNA localization to telomere
Process	2	0.0006	0.0224	Establishment of protein-containing complex localization to telomere
Process	2	0.0006	0.0224	Nucleotide-excision repair involved in interstrand cross-link repair
Process	2	0.0006	0.0224	Positive regulation of single strand break repair
Process	2	0.0006	0.0224	Positive regulation of telomerase catalytic core complex assembly
Process	2	0.0006	0.0224	Mitotic recombination-dependent replication fork processing
DISEASES	3	0.00042	0.023	Seckel syndrome
HPO	8	0.0014	0.0231	Abnormal metaphysis morphology
Process	5	0.00065	0.0234	Somitogenesis
Function	2	0.0006	0.0239	Polynucleotide 3-phosphatase activity
Function	2	0.0006	0.0239	DNA end binding
Function	2	0.0006	0.0239	8-oxo-7,8-dihydroguanine DNA N-glycosylase activity
Function	2	0.0006	0.0239	MutSbeta complex binding
Function	2	0.0006	0.0239	MutLbeta complex binding
Function	2	0.0006	0.0239	Site-specific endodeoxyribonuclease activity, specific for altered base
Function	2	0.0006	0.0239	Purine-specific mismatch base pair DNA N-glycosylase activity
Function	5	0.00061	0.0239	Promoter-specific chromatin binding
Function	2	0.0006	0.0239	Telomeric G-quadruplex DNA binding
Function	2	0.0006	0.0239	Forked DNA-dependent helicase activity
Function	2	0.0006	0.0239	DNA clamp unloader activity
Function	2	0.0006	0.0239	FHA domain binding
WikiPathways	4	0.0018	0.0239	Hepatitis C and hepatocellular carcinoma
RCTM	2	0.002	0.024	Activation of NOXA and translocation to mitochondria
RCTM	2	0.002	0.024	Diseases of Base Excision Repair
RCTM	2	0.002	0.024	Drug-mediated inhibition of CDK4/CDK6 activity
Keyword	10	0.0016	0.024	Iron
HPO	2	0.0015	0.0242	Small anterior fontanelle
TISSUES	7	0.00029	0.0249	B-lymphocyte cell line
WikiPathways	3	0.002	0.025	Progeria-associated lipodystrophy
WikiPathways	3	0.002	0.025	NAD metabolism in oncogene-induced senescence and mitochondrial dysfunction-associated senescence
HPO	3	0.0015	0.0251	Panhypogammaglobulinemia
HPO	3	0.0015	0.0251	Vitiligo
HPO	3	0.0015	0.0251	Abnormal femoral metaphysis morphology
HPO	7	0.0015	0.0251	Abnormality of hair texture
HPO	3	0.0015	0.0251	Hodgkin lymphoma
Process	6	0.00071	0.0254	DNA modification
Keyword	32	0.0017	0.0254	Transferase
HPO	17	0.0016	0.0256	Eosinophil count
HPO	4	0.0016	0.0259	Dysdiadochokinesis
HPO	4	0.0016	0.0259	Breast hypoplasia
Process	7	0.00073	0.026	Regulation of B cell activation
Pfam	3	5.4e-05	0.0266	FAT domain
Pfam	3	1.96e-05	0.0266	DNA ligase N terminus
Pfam	3	1.96e-05	0.0266	ATP dependent DNA ligase C terminal region        
Pfam	3	1.96e-05	0.0266	GINS complex protein
Pfam	3	3.4e-05	0.0266	RecQ zinc-binding
Pfam	3	1.96e-05	0.0266	DNA polymerase alpha/epsilon subunit B
Component	2	0.0015	0.0273	CHRAC
Component	2	0.0015	0.0273	BRCA1-BARD1 complex
COMPARTMENTS	29	0.0015	0.0274	Cytoskeleton
COMPARTMENTS	2	0.0015	0.0275	Rad6-Rad18 complex
COMPARTMENTS	2	0.0015	0.0275	Shu complex
COMPARTMENTS	2	0.0015	0.0275	Single-stranded DNA-binding protein complex
COMPARTMENTS	2	0.0015	0.0275	Rhp55-Rhp57 complex
COMPARTMENTS	2	0.0015	0.0275	BRCA1-BARD1 complex
COMPARTMENTS	2	0.0015	0.0275	CENP-T-W-S-X complex
HPO	4	0.0017	0.0277	Keratinocyte carcinoma
DISEASES	3	0.00051	0.0278	In situ carcinoma
HPO	5	0.0018	0.0284	Intention tremor
Process	36	0.0008	0.0284	Positive regulation of cellular biosynthetic process
HPO	17	0.0018	0.0287	Abnormal thorax morphology
Component	4	0.0016	0.0288	Nuclear ubiquitin ligase complex
Process	4	0.00082	0.0292	Regulation of isotype switching
HPO	9	0.0018	0.0293	Abnormality of the pituitary gland
KEGG	6	0.0033	0.0297	Measles
HPO	13	0.0019	0.0298	Tremor
Process	18	0.00085	0.03	Gamete generation
HPO	6	0.0019	0.0301	Cerebral calcification
HPO	6	0.0019	0.0301	Abnormal temporal lobe morphology
HPO	6	0.0019	0.0301	Autoimmunity
WikiPathways	3	0.0024	0.0304	miRNA regulation of p53 pathway in prostate cancer
HPO	3	0.002	0.0312	Ridged nail
HPO	4	0.002	0.0314	Pathologic fracture
HPO	8	0.002	0.0314	Thick vermilion border
HPO	4	0.002	0.0314	Recurrent viral infections
Process	4	0.0009	0.0317	Positive regulation of double-strand break repair via homologous recombination
Process	4	0.0009	0.0317	Regulation of intrinsic apoptotic signaling pathway in response to DNA damage
HPO	31	0.002	0.032	Abnormality of digestive system physiology
DISEASES	2	0.0006	0.0322	Obsolete papillomavirus infectious disease
DISEASES	4	0.00062	0.0322	Severe combined immunodeficiency
DISEASES	2	0.0006	0.0322	Familial retinoblastoma
DISEASES	2	0.0006	0.0322	Xeroderma pigmentosum group B
DISEASES	2	0.0006	0.0322	Fanconi anemia complementation group I
DISEASES	2	0.0006	0.0322	Fanconi anemia complementation group T
DISEASES	2	0.0006	0.0322	Meier-Gorlin syndrome 5
DISEASES	2	0.0006	0.0322	XFE progeroid syndrome
HPO	6	0.002	0.0322	Arthralgia
DISEASES	2	0.0006	0.0322	Fanconi anemia complementation group Q
HPO	2	0.002	0.0323	Absent sternal ossification
WikiPathways	2	0.0027	0.033	Metastatic brain tumor
WikiPathways	2	0.0027	0.033	lncRNA-mediated mechanisms of therapeutic resistance
Process	6	0.00095	0.0332	Hematopoietic progenitor cell differentiation
HPO	6	0.0021	0.0334	Aminoaciduria
HPO	4	0.0021	0.0334	Mild global developmental delay
HPO	6	0.0022	0.0344	Microcornea
HPO	3	0.0022	0.0344	Bilateral microphthalmos
HPO	3	0.0022	0.0344	Abnormal auditory evoked potentials
Process	2	0.00099	0.0345	Replication fork reversal
Process	2	0.00099	0.0345	Negative regulation of t-circle formation
Process	2	0.00099	0.0345	Mitotic telomere maintenance via semi-conservative replication
Process	2	0.00099	0.0345	Negative regulation of transcription involved in G1/S transition of mitotic cell cycle
Process	3	0.001	0.0345	Positive regulation of DNA damage response, signal transduction by p53 class mediator
Process	2	0.00099	0.0345	Replication fork arrest
Process	2	0.00099	0.0345	Small-subunit processome assembly
Process	2	0.00099	0.0345	DNA ADP-ribosylation
Process	2	0.00099	0.0345	Peptidyl-serine ADP-ribosylation
Process	8	0.001	0.0345	Peptidyl-serine phosphorylation
Process	2	0.00099	0.0345	Negative regulation of protein ADP-ribosylation
Process	3	0.001	0.0345	Positive regulation of double-strand break repair via nonhomologous end joining
WikiPathways	4	0.0029	0.0346	Overlap between signal transduction pathways contributing to LMNA laminopathies
Function	5	0.00095	0.0348	p53 binding
SMART	2	0.0006	0.0349	Poly(ADP-ribose) polymerase and DNA-Ligase Zn-finger region
SMART	2	0.0006	0.0349	CDC6, C terminal
SMART	2	0.0006	0.0349	This DNA-binding domain is found in the RecQ helicase among others and has a helix-turn-helix structure. The RQC domain, found only in RecQ family enzymes, is a high affinity G4 DNA binding domain PUBMED:16530788.
SMART	2	0.0006	0.0349	Ku70 and Ku80 are 70kDa and 80kDa subunits of the Lupus Ku autoantigen
HPO	10	0.0022	0.0351	Abnormality of the thyroid gland
WikiPathways	6	0.0031	0.0356	Measles virus infection
Function	2	0.00099	0.0357	DNA polymerase processivity factor activity
Function	2	0.00099	0.0357	DNA insertion or deletion binding
Function	2	0.00099	0.0357	Flap-structured DNA binding
Function	2	0.00099	0.0357	NAD DNA ADP-ribosyltransferase activity
Function	2	0.00099	0.0357	8-hydroxy-2-deoxyguanosine DNA binding
COMPARTMENTS	2	0.002	0.0364	CHRAC
COMPARTMENTS	2	0.002	0.0364	Cyclin-dependent protein kinase activating kinase holoenzyme complex
COMPARTMENTS	2	0.002	0.0364	Rad51C-XRCC3 complex
COMPARTMENTS	2	0.002	0.0364	MutLgamma complex
Component	2	0.002	0.0367	Cul4B-RING E3 ubiquitin ligase complex
Component	2	0.002	0.0367	Elongin complex
HPO	7	0.0024	0.0376	Peripheral axonal degeneration
HPO	4	0.0024	0.0377	Erythroderma
HPO	4	0.0024	0.0377	Abnormal T cell subset distribution
HPO	3	0.0024	0.038	Endometrial carcinoma
HPO	3	0.0024	0.038	Keratoconjunctivitis sicca
HPO	10	0.0024	0.038	Gastroesophageal reflux
HPO	6	0.0025	0.0381	Athetosis
HPO	6	0.0025	0.0381	Abnormal glial cell morphology
HPO	5	0.0025	0.0383	Kinetic tremor
HPO	7	0.0026	0.0394	Cancer
Process	17	0.0012	0.0395	Protein localization to organelle
Process	3	0.0012	0.0395	DNA catabolic process, endonucleolytic
HPO	16	0.0026	0.0397	Abnormal cerebral cortex morphology
RCTM	2	0.0035	0.0398	RUNX3 regulates CDKN1A transcription
KEGG	5	0.0045	0.0401	HIF-1 signaling pathway
RCTM	4	0.0035	0.0402	Formation of RNA Pol II elongation complex
HPO	18	0.0026	0.0405	Functional abnormality of the gastrointestinal tract
InterPro	4	0.00041	0.0405	Cyclin, N-terminal
Function	25	0.0012	0.041	Protein-containing complex binding
HPO	14	0.0027	0.0412	Respiratory insufficiency
HPO	2	0.0027	0.0414	Impaired distal proprioception
HPO	2	0.0027	0.0414	Multiple mitochondrial DNA deletions
HPO	8	0.0027	0.0416	Abnormality of the menstrual cycle
HPO	3	0.0027	0.0416	Decreased lacrimation
DISEASES	13	0.00087	0.0416	Cell type cancer
DISEASES	3	0.00086	0.0416	Ovarian carcinoma
Process	10	0.0013	0.0431	Cellular response to peptide
Process	14	0.0013	0.0438	Response to inorganic substance
RCTM	4	0.0039	0.0446	Meiotic synapsis
SMART	2	0.00099	0.0449	Proposed nucleic acid binding domain
SMART	2	0.00099	0.0449	DNA polymerase A domain
SMART	2	0.00099	0.0449	Endonuclease III
SMART	2	0.00099	0.0449	Helicase and RNase D C-terminal
Process	9	0.0013	0.0452	Response to alcohol
Process	28	0.0013	0.0452	Regulation of programmed cell death
HPO	3	0.003	0.0459	Absent Achilles reflex
HPO	3	0.003	0.0459	Anhidrosis
DISEASES	2	0.00099	0.0462	Sensory ataxic neuropathy, dysarthria, and ophthalmoparesis
DISEASES	2	0.00099	0.0462	Peritoneal carcinoma
DISEASES	2	0.00099	0.0462	Lung squamous cell carcinoma
DISEASES	2	0.00099	0.0462	Isolated growth hormone deficiency type IA
COMPARTMENTS	2	0.0027	0.0464	RQC complex
COMPARTMENTS	2	0.0027	0.0464	Cul4B-RING E3 ubiquitin ligase complex
KEGG	7	0.0054	0.0469	Human immunodeficiency virus 1 infection
HPO	8	0.0031	0.0471	Abnormality of the anterior pituitary
InterPro	9	0.00048	0.0476	Winged helix DNA-binding domain superfamily
HPO	6	0.0032	0.0479	Lymphadenopathy
RCTM	2	0.0043	0.0485	Activation of PUMA and translocation to mitochondria
Process	2	0.0015	0.0492	Depurination
Process	2	0.0015	0.0492	Meiotic DNA double-strand break processing
Process	2	0.0015	0.0492	Pyrimidine dimer repair by nucleotide-excision repair
Process	2	0.0015	0.0492	pro-B cell differentiation
Process	2	0.0015	0.0492	Maintenance of mitotic sister chromatid cohesion
Process	2	0.0015	0.0492	DNA replication, removal of RNA primer
Process	30	0.0015	0.0492	Regulation of cell death
Process	2	0.0015	0.0492	Cellular response to cisplatin
HPO	8	0.0033	0.0494	Neoplasm
Process	5	0.0015	0.0494	Stem cell proliferation
TISSUES	9	0.0006	0.0498	Fibroblast
TISSUES	2	0.0006	0.0498	WI-38 cell
TISSUES	2	0.0006	0.0498	CHO-EM9 cell
TISSUES	2	0.0006	0.0498	DT-40 cell
TISSUES	2	0.0006	0.0498	Oropharynx
TISSUES	2	0.0006	0.0498	46BR.1G1 cell
